var title_f30_51_31536="Bilirubin in hepatocytes";
var content_f30_51_31536=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F52393&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F52393&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 474px\">",
"   <div class=\"ttl\">",
"    Bilirubin throughput in hepatocytes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 454px; height: 467px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    UDP: uridine diphosphate; UDPGA: uridine 5'-diphosphoglucuronic acid.",
"    <br>",
"     <br>",
"      Schematic representation of the steps involved in bilirubin (B) throughput in hepatocytes: transport to the liver (primarily as albumin-bound bilirubin), uptake at the sinusoidal membrane, intracellular binding, conjugation (glucuronidation), and canalicular excretion. Sinusoidal bilirubin uptake requires inorganic anions, such as chloride, and is thought to be mediated by carrier proteins. Within the hepatocyte, bilirubin binds to glutathione S-transferases (GSTs). GST-binding reduces the efflux of the internalized bilirubin, thereby increasing the net uptake. GSTs also bind bilirubin glucuronides prior to excretion. Bilirubin also enters hepatocytes by passive diffusion. Glucuronidation of bilirubin is mediated by a family of enzymes, termed uridine diphosphoglucuronosyltransferase (UGT), the most important of which is bilirubin-UGT-1 (UGT1A1). Conjugated bilirubin is secreted actively across the bile canalicular membrane of the hepatocyte against a concentration gradient that may reach 1:1000. The canalicular multi-drug resistance protein 2 (MRP2) appears to be the most important for the canalicular secretion of bilirubin.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_51_31536=[""].join("\n");
var outline_f30_51_31536=null;
var title_f30_51_31537="Seating pressure on coccyx";
var content_f30_51_31537=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F59325&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F59325&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Seating position and coccydynia (pain in the coccyx)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 374px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_51_31537=[""].join("\n");
var outline_f30_51_31537=null;
var title_f30_51_31538="Patient information: Testicular cancer (The Basics)";
var content_f30_51_31538=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15502\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/43/22194\">",
"         Male reproductive anatomy",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?10/57/11154\">",
"         Patient information: Preserving fertility after cancer treatment in men (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?36/16/37121\">",
"         Patient information: What are clinical trials? (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?21/42/22180\">",
"         Patient information: Evaluation of the infertile couple (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?24/4/24645\">",
"         Patient information: Testicular cancer (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?32/5/32851\">",
"         Patient information: Treatment of male infertility (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Testicular cancer (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/testicular-cancer-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H551987977\">",
"      <span class=\"h1\">",
"       What is testicular cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Testicular cancer happens when normal cells in one or both testicles change into abnormal cells and grow out of control. The testicles are two ball-shaped organs that hang between a man&rsquo;s legs, inside a skin sac called the scrotum (",
"      <a class=\"graphic graphic_figure graphicRef68075 \" href=\"mobipreview.htm?21/43/22194\">",
"       figure 1",
"      </a>",
"      ). The testicles make sperm and male hormones.",
"     </p>",
"     <p>",
"      Testicular cancer occurs most often in boys and men ages 15 to 35. There are different types of testicular cancer. But most testicular cancer can be cured with treatment.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H551987984\">",
"      <span class=\"h1\">",
"       What are the symptoms of testicular cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The first symptom of testicular cancer is often a lump or swelling in the scrotum that is not painful. Other symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A dull ache or heavy feeling in the low belly, or around the anus or scrotum",
"       </li>",
"       <li>",
"        Pain in the testicles or scrotum",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      These symptoms can be caused by conditions that are not cancer. But if you feel a lump in your testicle, you should see your doctor or nurse as soon as possible.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H551987991\">",
"      <span class=\"h1\">",
"       Is there a test for testicular cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If your doctor or nurse suspects you have testicular cancer, he or she might order one or both of the following:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Testicular ultrasound &ndash; An ultrasound is an imaging test that creates pictures of the inside of the body and can show abnormal growths.",
"       </li>",
"       <li>",
"        Surgery &ndash; The only way to know for sure if a man has testicular cancer is for a doctor to remove the abnormal testicle. Another doctor will look at cells from the testicle under a microscope to see if cancer is present.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H551987998\">",
"      <span class=\"h1\">",
"       What is cancer staging?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Cancer staging is a way in which doctors find out if the cancer has spread beyond the testicles to other parts of the body. Staging usually involves blood tests, CT scans, or other imaging tests.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H551988005\">",
"      <span class=\"h1\">",
"       How is testicular cancer treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Removing the testicle is the first part of treatment. Further treatment will depend a lot on the type and stage of the cancer, and on where it has spread. After the testicle is removed, some men have a fake testicle put in. That way it looks like they still have 2 testicles.",
"     </p>",
"     <p>",
"      Some men whose testicular cancer is small might not need any further treatment after their testicle is removed. Other men with testicular cancer might have one or more of the following treatments:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Chemotherapy",
"        </strong>",
"        &ndash; Chemotherapy is the term doctors use to describe a group of medicines that kill cancer cells.",
"       </li>",
"       <li>",
"        <strong>",
"         Radiation therapy",
"        </strong>",
"        &ndash; Radiation kills cancer cells.",
"       </li>",
"       <li>",
"        <strong>",
"         Surgery",
"        </strong>",
"        &ndash; Testicular cancer is sometimes treated with surgery to remove nearby lymph nodes, which are bean-shaped internal organs. This surgery can help prevent the spread of testicular cancer in the body. A doctor might also do surgery to remove a mass in another part of the body if the cancer has spread.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H551988012\">",
"      <span class=\"h1\">",
"       What if I want to father a child one day?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you want to father a child one day, talk with your doctor. Treatments for testicular cancer can reduce or stop sperm production. Some men choose to store their sperm before treatment so they can use it in the future to have a child.",
"     </p>",
"     <p>",
"      Treatment for testicular cancer can make it hard to get a woman pregnant, but it does not usually affect a man&rsquo;s ability to get an erection. After treatment some men stop releasing fluid when they orgasm. This can be upsetting.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H551988019\">",
"      <span class=\"h1\">",
"       What happens after treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After treatment, you will be checked every so often to see if the cancer comes back. Follow-up tests usually include exams, blood tests, and imaging tests such as X-rays and CT scans.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H551988026\">",
"      <span class=\"h1\">",
"       What happens if the cancer comes back or spreads?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If the cancer comes back or spreads, you might have more chemotherapy, radiation therapy, or surgery.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H551988033\">",
"      <span class=\"h1\">",
"       What else should I do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It is important to follow all your doctors&rsquo; instructions about visits and tests. It&rsquo;s also important to talk to your doctor about any side effects or problems you have during treatment.",
"     </p>",
"     <p>",
"      Getting treated for testicular cancer involves making many choices, such as what treatment to have.",
"     </p>",
"     <p>",
"      Always let your doctors and nurses know how you feel about a treatment. Any time you are offered a treatment, ask:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        What are the benefits of this treatment? Is it likely to help me live longer? Will it reduce or prevent symptoms?",
"       </li>",
"       <li>",
"        What are the downsides to this treatment?",
"       </li>",
"       <li>",
"        Are there other options besides this treatment?",
"       </li>",
"       <li>",
"        What happens if I do not have this treatment?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H551988040\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/16/37121?source=see_link\">",
"       Patient information: What are clinical trials? (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/57/11154?source=see_link\">",
"       Patient information: Preserving fertility after cancer treatment in men (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/4/24645?source=see_link\">",
"       Patient information: Testicular cancer (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/5/32851?source=see_link\">",
"       Patient information: Treatment of male infertility (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/42/22180?source=see_link\">",
"       Patient information: Evaluation of the infertile couple (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?30/51/31538?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15502 Version 5.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-1745D172DA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_51_31538=[""].join("\n");
var outline_f30_51_31538=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H551987977\">",
"      What is testicular cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H551987984\">",
"      What are the symptoms of testicular cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H551987991\">",
"      Is there a test for testicular cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H551987998\">",
"      What is cancer staging?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H551988005\">",
"      How is testicular cancer treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H551988012\">",
"      What if I want to father a child one day?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H551988019\">",
"      What happens after treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H551988026\">",
"      What happens if the cancer comes back or spreads?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H551988033\">",
"      What else should I do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H551988040\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15502\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/43/22194\">",
"      Male reproductive anatomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/42/22180?source=related_link\">",
"      Patient information: Evaluation of the infertile couple (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/57/11154?source=related_link\">",
"      Patient information: Preserving fertility after cancer treatment in men (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/4/24645?source=related_link\">",
"      Patient information: Testicular cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/5/32851?source=related_link\">",
"      Patient information: Treatment of male infertility (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/16/37121?source=related_link\">",
"      Patient information: What are clinical trials? (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_51_31539="Calculator: A-a gradient (alveolar-arterial gradient; AaG)";
var content_f30_51_31539=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"AAGradient_form\" name=\"AAGradient_form\" onkeydown=\"clrResults();\" onkeyup=\"AAGradient_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: A-a gradient (alveolar-arterial gradient; AaG)",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <div id=\"calc_equation\">",
"      <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"       <tr>",
"        <td align=\"left\" bgcolor=\"#6c9a9c\">",
"         <span class=\"medCalcFontFormuli\">",
"          ExpectedAaG = 2.5 + (0.21 * Age)",
"         </span>",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"left\" bgcolor=\"#6c9a9c\">",
"         <span class=\"medCalcFontFormuli\">",
"          MeasuredAaG = (FIO2 * (pAtm - pH2O)) - (pCO2 / RespQuot) + (pCO2 * FIO2 * (1 - RespQuot) / RespQuot) - paO2",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"     </div>",
"    </center>",
"    <div id=\"calc_main\">",
"     <center>",
"      <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"       <tr>",
"        <td align=\"right\" width=\"50%\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Input:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Age",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Age_param\" onblur=\"AAGradient_fx(); minMaxCheck();\" onchange=\"AAGradient_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Age_unit\" onchange=\"AAGradient_fx();\" style=\"width:105px;\">",
"              <option value=\"0.0833333333333333|0|mo\">",
"               mo",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|yr\">",
"               yr",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Patient Temp",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Patient_Temp_param\" onblur=\"AAGradient_fx(); minMaxCheck();\" onchange=\"AAGradient_fx();\" size=\"6\" type=\"text\" value=\"37\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Patient_Temp_unit\" onchange=\"AAGradient_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|degC\">",
"               degC",
"              </option>",
"              <option value=\"0.555555555555556|-17.7777777777778|degF\">",
"               degF",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Elevation",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Elevation_param\" onblur=\"AAGradient_fx(); minMaxCheck();\" onchange=\"AAGradient_fx();\" size=\"6\" type=\"text\" value=\"0\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Elevation_unit\" onchange=\"AAGradient_fx();\" style=\"width:105px;\">",
"              <option value=\"0.01|0|cm\">",
"               cm",
"              </option>",
"              <option value=\"0.3048|0|ft\">",
"               ft",
"              </option>",
"              <option value=\"0.0254|0|in\">",
"               in",
"              </option>",
"              <option value=\"1e-06|0|micm\">",
"               micm",
"              </option>",
"              <option value=\"0.001|0|mm\">",
"               mm",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|m\">",
"               m",
"              </option>",
"              <option value=\"1e-09|0|nm\">",
"               nm",
"              </option>",
"              <option value=\"0.9144|0|yd\">",
"               yd",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Percent Inspired O2",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Percent_Inspired_O2_param\" onblur=\"AAGradient_fx(); minMaxCheck();\" onchange=\"AAGradient_fx();\" size=\"6\" type=\"text\" value=\"21\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Percent_Inspired_O2_unit\" onchange=\"AAGradient_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|%O2\">",
"               %O2",
"              </option>",
"              <option value=\"100|0|fractionO2\">",
"               fractionO2",
"              </option>",
"              <option value=\"3|21|litresO2\">",
"               litresO2",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              p CO2",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"p_CO2_param\" onblur=\"AAGradient_fx(); minMaxCheck();\" onchange=\"AAGradient_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"p_CO2_unit\" onchange=\"AAGradient_fx();\" style=\"width:105px;\">",
"              <option value=\"0.00750063755419211|0|Pascal\">",
"               Pascal",
"              </option>",
"              <option value=\"760.002100178515|0|atm\">",
"               atm",
"              </option>",
"              <option value=\"750.063755419211|0|bar\">",
"               bar",
"              </option>",
"              <option value=\"0.735561538478802|0|cmH2O\">",
"               cmH2O",
"              </option>",
"              <option value=\"10|0|cmHg\">",
"               cmHg",
"              </option>",
"              <option value=\"22.4199156928339|0|ftH2O\">",
"               ftH2O",
"              </option>",
"              <option value=\"0.735561538478802|0|gm/sqcm\">",
"               gm/sqcm",
"              </option>",
"              <option value=\"1.86832630773616|0|inH2O\">",
"               inH2O",
"              </option>",
"              <option value=\"25.4000840071406|0|inHg\">",
"               inHg",
"              </option>",
"              <option value=\"7.50063755419211|0|kPa\">",
"               kPa",
"              </option>",
"              <option value=\"0.750063755419211|0|mbar\">",
"               mbar",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mmHg\">",
"               mmHg",
"              </option>",
"              <option value=\"51.7150957831416|0|psi\">",
"               psi",
"              </option>",
"              <option value=\"1|0|torr\">",
"               torr",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Resp Quot",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Resp_Quot_param\" onblur=\"AAGradient_fx(); minMaxCheck();\" onchange=\"AAGradient_fx();\" size=\"6\" type=\"text\" value=\"0.8\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Resp_Quot_unit\" onchange=\"AAGradient_fx();\" style=\"width:105px;\">",
"              <option value=\"0.01|0|%\">",
"               %",
"              </option>",
"              <option value=\"1|0|fraction\">",
"               fraction",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|ratio\">",
"               ratio",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              p aO2",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"p_aO2_param\" onblur=\"AAGradient_fx(); minMaxCheck();\" onchange=\"AAGradient_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"p_aO2_unit\" onchange=\"AAGradient_fx();\" style=\"width:105px;\">",
"              <option value=\"0.00750063755419211|0|Pascal\">",
"               Pascal",
"              </option>",
"              <option value=\"760.002100178515|0|atm\">",
"               atm",
"              </option>",
"              <option value=\"750.063755419211|0|bar\">",
"               bar",
"              </option>",
"              <option value=\"0.735561538478802|0|cmH2O\">",
"               cmH2O",
"              </option>",
"              <option value=\"10|0|cmHg\">",
"               cmHg",
"              </option>",
"              <option value=\"22.4199156928339|0|ftH2O\">",
"               ftH2O",
"              </option>",
"              <option value=\"0.735561538478802|0|gm/sqcm\">",
"               gm/sqcm",
"              </option>",
"              <option value=\"1.86832630773616|0|inH2O\">",
"               inH2O",
"              </option>",
"              <option value=\"25.4000840071406|0|inHg\">",
"               inHg",
"              </option>",
"              <option value=\"7.50063755419211|0|kPa\">",
"               kPa",
"              </option>",
"              <option value=\"0.750063755419211|0|mbar\">",
"               mbar",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mmHg\">",
"               mmHg",
"              </option>",
"              <option value=\"51.7150957831416|0|psi\">",
"               psi",
"              </option>",
"              <option value=\"1|0|torr\">",
"               torr",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Results:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Expected AaG",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"Expected_AaG_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"            <td valign=\"top\">",
"             <span class=\"medCalcFontOne\">",
"              <select class=\"medCalcFontSelect\" name=\"Expected_AaG_unit\" onchange=\"AAGradient_fx();\" style=\"width:105px;\">",
"               <option value=\"0.00750063755419211|0|Pascal\">",
"                Pascal",
"               </option>",
"               <option value=\"760.002100178515|0|atm\">",
"                atm",
"               </option>",
"               <option value=\"750.063755419211|0|bar\">",
"                bar",
"               </option>",
"               <option value=\"0.735561538478802|0|cmH2O\">",
"                cmH2O",
"               </option>",
"               <option value=\"10|0|cmHg\">",
"                cmHg",
"               </option>",
"               <option value=\"22.4199156928339|0|ftH2O\">",
"                ftH2O",
"               </option>",
"               <option value=\"0.735561538478802|0|gm/sqcm\">",
"                gm/sqcm",
"               </option>",
"               <option value=\"1.86832630773616|0|inH2O\">",
"                inH2O",
"               </option>",
"               <option value=\"25.4000840071406|0|inHg\">",
"                inHg",
"               </option>",
"               <option value=\"7.50063755419211|0|kPa\">",
"                kPa",
"               </option>",
"               <option value=\"0.750063755419211|0|mbar\">",
"                mbar",
"               </option>",
"               <option selected=\"selected\" value=\"1|0|mmHg\">",
"                mmHg",
"               </option>",
"               <option value=\"51.7150957831416|0|psi\">",
"                psi",
"               </option>",
"               <option value=\"1|0|torr\">",
"                torr",
"               </option>",
"              </select>",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Measured AaG",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"Measured_AaG_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"            <td valign=\"top\">",
"             <span class=\"medCalcFontOne\">",
"              <select class=\"medCalcFontSelect\" name=\"Measured_AaG_unit\" onchange=\"AAGradient_fx();\" style=\"width:105px;\">",
"               <option value=\"0.00750063755419211|0|Pascal\">",
"                Pascal",
"               </option>",
"               <option value=\"760.002100178515|0|atm\">",
"                atm",
"               </option>",
"               <option value=\"750.063755419211|0|bar\">",
"                bar",
"               </option>",
"               <option value=\"0.735561538478802|0|cmH2O\">",
"                cmH2O",
"               </option>",
"               <option value=\"10|0|cmHg\">",
"                cmHg",
"               </option>",
"               <option value=\"22.4199156928339|0|ftH2O\">",
"                ftH2O",
"               </option>",
"               <option value=\"0.735561538478802|0|gm/sqcm\">",
"                gm/sqcm",
"               </option>",
"               <option value=\"1.86832630773616|0|inH2O\">",
"                inH2O",
"               </option>",
"               <option value=\"25.4000840071406|0|inHg\">",
"                inHg",
"               </option>",
"               <option value=\"7.50063755419211|0|kPa\">",
"                kPa",
"               </option>",
"               <option value=\"0.750063755419211|0|mbar\">",
"                mbar",
"               </option>",
"               <option selected=\"selected\" value=\"1|0|mmHg\">",
"                mmHg",
"               </option>",
"               <option value=\"51.7150957831416|0|psi\">",
"                psi",
"               </option>",
"               <option value=\"1|0|torr\">",
"                torr",
"               </option>",
"              </select>",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td colspan=\"3\">",
"             &nbsp;",
"             <br/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"center\" colspan=\"3\">",
"             <span class=\"medCalcFontOneBold\">",
"              Decimal Precision:",
"             </span>",
"             <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"AAGradient_fx();\">",
"              <option>",
"               0",
"              </option>",
"              <option selected=\"selected\">",
"               1",
"              </option>",
"              <option>",
"               2",
"              </option>",
"              <option>",
"               3",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <center>",
"          <span class=\"medCalcFontOne\">",
"           <input name=\"reset\" type=\"reset\" value=\"Reset form\"/>",
"          </span>",
"         </center>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOne\">",
"     </span>",
"    </div>",
"    <div id=\"calc_notes\">",
"     <span class=\"medCalcFontOneBold\">",
"      Notes",
"     </span>",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       High A-a gradients are associated with oxygen transfer / gas exchange problems. These are usually associated with alveolar membrane diseases, interstitial diseases or V/Q mismatch.",
"      </li>",
"      <li>",
"       Hypoxemia in the face of a normal A-a gradient implies hypoventilation with displacement of alveolar O2 by CO2 or other substance.",
"      </li>",
"      <li>",
"       The",
"       <b>",
"        FIO2",
"       </b>",
"       (fraction of inspired oxygen) is equal to the",
"       <b>",
"        Percent Inspired O2",
"       </b>",
"       / 100.",
"      </li>",
"      <li>",
"       In this calculator,",
"       <b>",
"        pATM",
"       </b>",
"       is estimated by elevation above sea level using this formula:",
"       <b>",
"        pAtm",
"       </b>",
"       = 760 * eTo(",
"       <b>",
"        Elevation",
"       </b>",
"       / -7000)",
"      </li>",
"      <li>",
"       <b>",
"        pH2O",
"       </b>",
"       is dependent on body temperature and calculated with the following formula:",
"       <b>",
"        pH2O",
"       </b>",
"       = 47 * eTo((",
"       <b>",
"        Patient Temp",
"       </b>",
"       - 37) / 18.4)",
"      </li>",
"      <li>",
"       The equation for expected A-a gradient assumes the patient is breathing room air; therefore, it is less accurate at higher percentages of inspired oxygen.",
"      </li>",
"     </ul>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Kanber GJ, King FW, Eshchar YR, et. al. The alveolar-arterial oxygen gradient in young and elderly men during air and oxygen breathing.",
"        <i>",
"         Am Rev Respir Dis",
"        </i>",
"        . 1968 Mar;97(3):376-81.",
"       </span>",
"      </li>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Mellemgaard K. The alveolar-arterial oxygen difference: its size and components in normal man.",
"        <i>",
"         Acta Physiol Scand",
"        </i>",
"        . 1966 May;67(1):10-20.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_51_31539=[" ",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function AAGradient_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.AAGradient_form){",
"",
"",
"doCalc = true;",
"if (Age_param.value.indexOf(',') >= 0){ Age_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Age_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Age_unit.options[Age_unit.selectedIndex].value.split('|');",
"Age = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Patient_Temp_param.value.indexOf(',') >= 0){ Patient_Temp_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Patient_Temp_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Patient_Temp_unit.options[Patient_Temp_unit.selectedIndex].value.split('|');",
"Patient_Temp = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Elevation_param.value.indexOf(',') >= 0){ Elevation_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Elevation_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Elevation_unit.options[Elevation_unit.selectedIndex].value.split('|');",
"Elevation = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Percent_Inspired_O2_param.value.indexOf(',') >= 0){ Percent_Inspired_O2_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Percent_Inspired_O2_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Percent_Inspired_O2_unit.options[Percent_Inspired_O2_unit.selectedIndex].value.split('|');",
"Percent_Inspired_O2 = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (p_CO2_param.value.indexOf(',') >= 0){ p_CO2_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(p_CO2_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = p_CO2_unit.options[p_CO2_unit.selectedIndex].value.split('|');",
"p_CO2 = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Resp_Quot_param.value.indexOf(',') >= 0){ Resp_Quot_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Resp_Quot_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Resp_Quot_unit.options[Resp_Quot_unit.selectedIndex].value.split('|');",
"Resp_Quot = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (p_aO2_param.value.indexOf(',') >= 0){ p_aO2_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(p_aO2_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = p_aO2_unit.options[p_aO2_unit.selectedIndex].value.split('|');",
"p_aO2 = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"dp = decpts.options[decpts.selectedIndex].text;",
"p_Atm =  760 * eTo(Elevation / -7000);",
"",
"p_H2O =  47 * eTo((Patient_Temp - 37) / 18.4);",
"",
"FIO2 =  Percent_Inspired_O2 / 100;",
"",
"Expected_AaG =  2.5 + (0.21 * Age);",
"",
"unit_parts = Expected_AaG_unit.options[Expected_AaG_unit.selectedIndex].value.split('|');",
"if (doCalc) Expected_AaG_param.value = fixDP((Expected_AaG - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"Measured_AaG =  (FIO2 * (p_Atm - p_H2O)) - (p_CO2 / Resp_Quot) + (p_CO2 * FIO2 * (1 - Resp_Quot) / Resp_Quot) - p_aO2;",
"",
"unit_parts = Measured_AaG_unit.options[Measured_AaG_unit.selectedIndex].value.split('|');",
"if (doCalc) Measured_AaG_param.value = fixDP((Measured_AaG - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.AAGradient_form){",
"",
"if (Age_param.value && Age < 0) {",
"Age = 0;",
"Age_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Age is 0 yr.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Age_param.value && Age > 120) {",
"Age_param.value = \"\";",
"clrResults();",
"Age = 0;",
"doCalc = false;",
"alert(\"The maximum value for Age is 120 yr.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Patient_Temp_param.value && Patient_Temp < 20) {",
"Patient_Temp = 0;",
"Patient_Temp_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Patient Temp is 20 degC.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Patient_Temp_param.value && Patient_Temp > 40) {",
"Patient_Temp_param.value = \"\";",
"clrResults();",
"Patient_Temp = 0;",
"doCalc = false;",
"alert(\"The maximum value for Patient Temp is 40 degC.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Elevation_param.value && Elevation < 0) {",
"Elevation = 0;",
"Elevation_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Elevation is 0 m.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Elevation_param.value && Elevation > 10000) {",
"Elevation_param.value = \"\";",
"clrResults();",
"Elevation = 0;",
"doCalc = false;",
"alert(\"The maximum value for Elevation is 10000 m.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Percent_Inspired_O2_param.value && Percent_Inspired_O2 < 1) {",
"Percent_Inspired_O2 = 0;",
"Percent_Inspired_O2_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Percent Inspired O2 is 1 %O2.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Percent_Inspired_O2_param.value && Percent_Inspired_O2 > 100) {",
"Percent_Inspired_O2_param.value = \"\";",
"clrResults();",
"Percent_Inspired_O2 = 0;",
"doCalc = false;",
"alert(\"The maximum value for Percent Inspired O2 is 100 %O2.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Resp_Quot_param.value && Resp_Quot < 0.01) {",
"Resp_Quot = 0;",
"Resp_Quot_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Resp Quot is 0.01 ratio.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Resp_Quot_param.value && Resp_Quot > 100) {",
"Resp_Quot_param.value = \"\";",
"clrResults();",
"Resp_Quot = 0;",
"doCalc = false;",
"alert(\"The maximum value for Resp Quot is 100 ratio.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.AAGradient_form){",
"",
"Expected_AaG_param.value = '';",
"Measured_AaG_param.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
""].join("\n");
var outline_f30_51_31539=null;
var title_f30_51_31540="Protein C concentrate: Patient drug information";
var content_f30_51_31540=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Protein C concentrate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/50/6949?source=see_link\">",
"     see \"Protein C concentrate: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/27/39349?source=see_link\">",
"     see \"Protein C concentrate: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F4594766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ceprotin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692061",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat very bad protein C deficiency.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702815",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to protein C or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701032",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to heparin or mouse proteins, talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697055",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are on a low-salt diet (this drug has salt), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697760",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care to stop injury and avoid falls or crashes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Allergic side effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into a vein for a period of time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10016519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10016524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Most of the time, this drug will be given to you in a doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If this drug is given at home, store unopened vials in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699645",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use within 3 hours of making.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699615",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away any part of opened vial not used after use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11888 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-C80C007BE0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_51_31540=[""].join("\n");
var outline_f30_51_31540=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4594766\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016516\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016515\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016520\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016521\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016523\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016518\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016519\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016524\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016525\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?6/50/6949?source=related_link\">",
"      Protein C concentrate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/27/39349?source=related_link\">",
"      Protein C concentrate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_51_31541="Candidiasis vulva";
var content_f30_51_31541=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F70637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F70637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 495px\">",
"   <div class=\"ttl\">",
"    Candidiasis vulva",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 475px; height: 343px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from&nbsp;Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_51_31541=[""].join("\n");
var outline_f30_51_31541=null;
var title_f30_51_31542="Nontyphoidal Salmonella bacteremia";
var content_f30_51_31542=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"16\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nontyphoidal Salmonella bacteremia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/51/31542/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/51/31542/contributors\">",
"     Elizabeth L Hohmann, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/51/31542/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/51/31542/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/51/31542/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/51/31542/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/51/31542/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nontyphoidal salmonellae are an important bacterial cause of diarrheal disease. The epidemiology and pathophysiology of nontyphoidal strains differ from typhoidal strains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31542/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/2/42024?source=see_link\">",
"     \"Epidemiology, microbiology, clinical manifestations, and diagnosis of typhoid fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues related to the epidemiology, clinical microbiology, clinical manifestations, and treatment of nontyphoidal Salmonella bacteremia will be reviewed here. Nontyphoidal Salmonella gastrointestinal disease and typhoid fever are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/8/26761?source=see_link\">",
"     \"Approach to the patient with nontyphoidal Salmonella in a stool culture\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/58/18345?source=see_link\">",
"     \"Treatment and prevention of typhoid fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacteremia and other forms of extraintestinal Salmonella infection are serious complications that may not be suspected in the setting of mild primary infection. It is estimated that perhaps 1 percent of enteric infections with nontyphoidal Salmonella result in bacteremia, but the true rate of bacteremia is unknown, as many primary enteric infections are mild or not microbiologically diagnosed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors affecting the incidence of bacteremia include Salmonella serotype, geographic location, time of year, and host factors. Host risk factors for nontyphoidal Salmonella bacteremia include extremes of age and chronic or immunosuppressing conditions, including malignancy, rheumatological disease, TNF blockade (eg, agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    ), transplantation, HIV infection, and congenital immune defects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31542/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. Other predisposing comorbidities include liver disease, hemoglobinopathies (especially sickle cell disease), schistosomiasis, and chronic granulomatous disease. Alteration of the GI tract also predisposes to progression from enteric to systemic salmonellosis (eg, by suppression of gastric acid, malnutrition, recent antibiotic use, or rotavirus infection) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31542/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/37/19033?source=see_link\">",
"     \"Pathogenesis of Salmonella gastroenteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a series of 55 Malaysian adults with nontyphoidal Salmonella bacteremia, over 90 percent of patients had an underlying medical illness; 65 percent had severe immunosuppression, most commonly HIV infection or malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31542/abstract/7\">",
"     7",
"    </a>",
"    ]. In sub-Saharan Africa nontyphoidal Salmonella bacteremia is a leading cause of bacteremia in adults and children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31542/abstract/7-12\">",
"     7-12",
"    </a>",
"    ]. Such infections may occur in epidemic waves and mortality may be very high (12 to 30 percent). Relapsing bacteremia and higher mortality are observed in the setting of concurrent HIV infection.",
"   </p>",
"   <p>",
"    Children with nontyphoidal bacteremia in developed settings usually have associated gastroenteritis, do not typically have underlying comorbid illness, and most recover uneventfully [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31542/abstract/6,13,14\">",
"     6,13,14",
"    </a>",
"    ]. In a series of 144 pediatric cases of nontyphoidal Salmonella bacteremia in Pittsburgh (median age 10.5 months), 82 percent of patients were previously healthy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31542/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood cultures should be drawn in patients with Salmonella gastroenteritis ill enough to require hospitalization. Nontyphoidal Salmonella are vigorous organisms that grow readily in aerobic and anaerobic blood culture bottles.",
"   </p>",
"   <p>",
"    Serotype distribution varies greatly by location and over time. S. enteritidis and S. typhimurium are the most commonly isolated pathogenic serotypes; therefore, they are also most frequently isolated from the blood. Some less frequently isolated serotypes can be more invasive than others and are more likely to cause bacteremia (including S. enterica serotypes Dublin, Cholerasuis, Virchow, Infantis, Newport, and Heidelberg) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31542/abstract/1,15\">",
"     1,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/19/14649?source=see_link\">",
"     \"Microbiology and epidemiology of salmonellosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A \"primary bacteremia\" (ie, a positive blood culture in the absence of recent or current gastrointestinal symptoms of Salmonella infection) may be an initial signal of unappreciated immunological dysfunction. HIV infection should be considered; recurrent Salmonella infection was a relatively frequent AIDS-defining infection in the US in the pre-HAART era. Other more frequently encountered co-morbidities include malignancy, diabetes, and rheumatologic illness. Therapeutic immunosuppression with steroids and other immunomodulatory drugs is increasingly common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Extraintestinal focal infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nontyphoidal salmonellae bacteremia can progress to development of infection at any site, including the urinary tract, lung, pleura, heart, long bones, joints, muscle, and central nervous system. After stool and blood, urinary isolates are encountered most frequently; these may reflect urologic abnormalities, bacteremia in the setting of chronic medical illness,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    retrograde spread of infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31542/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Salmonella meningitis is a rare complication that typically occurs in neonates and children &le;1 year; for this reason, any form of nontyphoidal salmonellosis in infants should prompt immediate and attentive management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31542/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Mortality is high and survivors may not have complete neurological recovery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/20/25930?source=see_link\">",
"     \"Diagnosis and treatment of gram-negative bacillary meningitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Endovascular infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endovascular infection is an uncommon but serious complication of nontyphoidal Salmonella bacteremia. Initially noted in the 1970s, subsequent population-based studies have noted that approximately 10 to 20 percent of adults over 50 years of age with documented nontyphoidal Salmonella bloodstream infections have a suppurative endovascular focus of infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31542/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. The organisms are presumed to home to existing atherosclerotic sites in large vessels in older adults; this is the rationale for a more aggressive approach to treatment of Salmonella gastroenteritis in older individuals. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/8/26761?source=see_link\">",
"     \"Approach to the patient with nontyphoidal Salmonella in a stool culture\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endovascular infection was specifically linked to atherosclerosis in one Taiwanese study, in the absence of other clinical features or immunodeficiencies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31542/abstract/22\">",
"     22",
"    </a>",
"    ]. The abdominal aorta (especially infrarenal) is the most frequent site of vascular infection, though involvement of the thoracic aorta, other central arterial sites and endocarditis occur as well. Subacute fever and abdominal and back pain are the typical presenting symptoms; a pulsatile mass is a late and ominous finding.",
"   </p>",
"   <p>",
"    The diagnostic approach should consist of CT or MRI (preferably with contrast angiographic analysis) when an aortic or vascular focus is possible or suspected. Medical therapy alone is inadequate; surgery is required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31542/abstract/23\">",
"     23",
"    </a>",
"    ]. Experienced vascular surgeons should be consulted. Because of the morbidity of extra-anatomic bypass, most experts perform in-situ debridement and grafting despite the risk of leak and relapsed infection. There are a variety of specific surgical approaches and grafts, depending on the site involved, intraoperative findings, and degree of debridement deemed necessary and achieved. Small surgical series of 23 and 24 patients have demonstrated a 60 to 100 percent survival rate, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31542/abstract/14,24\">",
"     14,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antibiotics are an essential component of therapy, but the duration of therapy is debated. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extraintestinal nontyphoidal Salmonella infections generally require surgical drainage or debridement and prolonged antimicrobial therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Antibiotic selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluoroquinolones are a reasonable empiric antibiotic choice for treatment of nontyphoidal Salmonella bacteremia (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    400 mg intravenously twice daily or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    500 to 750 mg intravenously once daily). Fluoroquinolones have excellent intracellular penetration and oral bioavailability, allowing transition to oral therapy with clinical improvement.",
"   </p>",
"   <p>",
"    Fluoroquinolones are frequently avoided in children because of cartilage abnormalities observed in developing animals, although data suggest that fluoroquinolones may be used in children over short courses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31542/abstract/25\">",
"     25",
"    </a>",
"    ]. Treatment of serious Salmonella infections is a reasonable indication for use of fluoroquinolones in children, especially if other agents are not readily available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31542/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/60/28618?source=see_link\">",
"     \"Fluoroquinolones\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Third generation cephalosporins are a reasonable alternative to fluoroquinolones (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    1 to 2 g intravenously once daily or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    2 g intravenously every eight hours).",
"   </p>",
"   <p>",
"    Reduced susceptibility and frank resistance to fluoroquinolones and third generation cephalosporins is increasing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31542/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Resistance has been reported frequently in Asia and history of travel to this region should be considered in clinical management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31542/abstract/29\">",
"     29",
"    </a>",
"    ]. Antibiotics must be tailored to susceptibility data once available. Nalidixic acid disc resistance testing should be performed if possible; resistance to nalidixic acid indicates relative resistance to fluoroquinolones and should prompt use of an alternative drug.",
"   </p>",
"   <p>",
"    Other reasonable antibiotic alternatives include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (8 to 10",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    component divided three times per day) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    (2 g IV every 4 hours).",
"   </p>",
"   <p>",
"    For management of infections due to highly resistant organisms, infectious disease consultation is advisable. Carbapenems are appropriate agents for treatment of infection due to highly resistant organisms; resistance to carbapenems has rarely been noted in case reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31542/abstract/30-32\">",
"     30-32",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     Azithromycin",
"    </a>",
"    is another possible alternative in exceptional cases, although there are no standard NCCLS antimicrobial susceptibility break points reported for salmonellae.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Bacteremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal duration of antimicrobial therapy for nontyphoidal Salmonella bacteremia in the absence of extraintestinal focal infection depends upon the immune status of the host. A 14 day course of antimicrobial therapy for otherwise healthy individuals is likely appropriate. Patients with Salmonella gastroenteritis hospitalized with the suspicion of bacteremia should have blood cultures drawn and empiric treatment initiated while awaiting culture results. In such circumstances, prompt initiation of antibiotic therapy is of greater clinical importance than the possibility of prolonging fecal carriage, especially in older patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/8/26761?source=see_link\">",
"     \"Approach to the patient with nontyphoidal Salmonella in a stool culture\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Longer courses of antimicrobial therapy (4 to 6 weeks) are warranted for patients with significant immunosuppression for whom recurrence or relapse is likely (eg, such as in the setting of",
"    <span class=\"nowrap\">",
"     HIV/AIDS,",
"    </span>",
"    solid organ transplant, or bone marrow transplant) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31542/abstract/8,33,34\">",
"     8,33,34",
"    </a>",
"    ]. If infection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bacteremia occurs at an immunological nadir in these patients, the infection may become established within the immunologically compromised reticuloendothelial system. Relapse may occur even after an asymptomatic interval and in the absence of a known focus of infection (such as osteomyelitis or an abnormal biliary or urinary system) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31542/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A period of suppressive therapy may also be appropriate for patients with significant immunosuppression, especially if relapse of bacteremia is documented after an initial successful treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Extraintestinal focal infections and endovascular infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, complete debridement and drainage of soft tissue or visceral foci of infection should be followed by a minimum of 3 weeks of antimicrobial therapy if there are no clinical complications. Extraintestinal foci are virtually always seeded by bacteremic spread, so the issues discussed in the preceding section apply.",
"   </p>",
"   <p>",
"    Longer courses of therapy (6 to 12 weeks) may be advisable depending upon the site, adequacy of surgical debridement achieved, presence of any prosthetic material (vascular grafts, joints, screws, plates, valves or other hardware), presence or absence remaining fluid collections or devitalized tissue, immunological status, and age of the patient. Duration of therapy should be commensurate with standard courses for the site of infection at a minimum; for example, a brain abscess, endocarditis, or osseous infection should be treated for at least 6 to 8 weeks if Salmonella are present.",
"   </p>",
"   <p>",
"    Salmonella are hardy organisms that adapt to stressful environments and may be difficult to eradicate, especially if devitalized tissue or prosthetic material is present. Chronic suppressive therapy may be appropriate for patients with infection of prosthetic joints, heart valves, or vascular grafts where the potential consequences of relapsed infection may be dire. Reasonable suppressive regimens (depending on the sensitivity of the organism) include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (one DS tablet once daily),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    (500 mg once daily) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    (750 mg once daily). Consultation with infectious disease expertise is recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/31/27122?source=see_link\">",
"       \"Patient information: Salmonellosis (Salmonella) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bacteremia and other forms of extraintestinal Salmonella infection are serious complications that may not be suspected in the setting of mild primary infection. Factors affecting the incidence of bacteremia include Salmonella serotype, geographic location, time of year, and host factors including extremes of age and immunosuppressing conditions. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nontyphoidal Salmonella bacteremia can progress to development of infection at any site, including any visceral organ, long bones, joints, muscle, and central nervous system. After stool and blood, urinary isolates are encountered most frequently. Salmonella meningitis is a rare complication that typically occurs in neonates and children &le;1 year. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Extraintestinal focal infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endovascular infection is a serious complication of nontyphoidal Salmonella bacteremia. The abdominal aorta (particularly the infrarenal aorta) is the most frequent site of infection. When a vascular focus of infection is suspected, CT or MRI with contrast should be performed. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Endovascular infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Extraintestinal nontyphoidal Salmonella infections generally require surgical drainage or debridement and prolonged antimicrobial therapy. Reasonable empiric antibiotics for treatment of nontyphoidal Salmonella bacteremia include fluoroquinolones (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      400 mg intravenously twice daily or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      500 to 750 mg intravenously once daily) or third generation cephalosporins (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      1 to 2 g intravenously once daily or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/57/35735?source=see_link\">",
"       cefotaxime",
"      </a>",
"      2 g intravenously every eight hours). Stable patients may receive fluoroquinolones orally, as they have excellent oral bioavailability (ciprofloxacin 500 mg twice daily or levofloxacin 500 to 750 mg once daily). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Antibiotic selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A 14 day course of antimicrobial therapy is likely adequate for otherwise healthy individuals with uncomplicated bacteremia accompanying gastroenteritis. Longer courses of antimicrobial therapy (4 to 6 weeks or more) are warranted for patients with significant immunosuppression for whom recurrence or relapse is likely. Suppressive therapy may also be appropriate for some patients, especially if relapse of bacteremia is documented after an initial successful treatment or prosthetic materials are present. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31542/abstract/1\">",
"      Mandal BK, Brennand J. Bacteraemia in salmonellosis: a 15 year retrospective study from a regional infectious diseases unit. BMJ 1988; 297:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31542/abstract/2\">",
"      Symmons DP, Silman AJ. The world of biologics. Lupus 2006; 15:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31542/abstract/3\">",
"      Garcia-Vidal C, Rodr&iacute;guez-Fern&aacute;ndez S, Teij&oacute;n S, et al. Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention. Eur J Clin Microbiol Infect Dis 2009; 28:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31542/abstract/4\">",
"      Katsarolis I, Tsiodras S, Panagopoulos P, et al. Septic arthritis due to Salmonella enteritidis associated with infliximab use. Scand J Infect Dis 2005; 37:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31542/abstract/5\">",
"      Gordon MA. Salmonella infections in immunocompromised adults. J Infect 2008; 56:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31542/abstract/6\">",
"      Hung TY, Liu MC, Hsu CF, Lin YC. Rotavirus infection increases the risk of bacteremia in children with nontyphoid Salmonella gastroenteritis. Eur J Clin Microbiol Infect Dis 2009; 28:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31542/abstract/7\">",
"      Dhanoa A, Fatt QK. Non-typhoidal Salmonella bacteraemia: epidemiology, clinical characteristics and its' association with severe immunosuppression. Ann Clin Microbiol Antimicrob 2009; 8:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31542/abstract/8\">",
"      Gordon MA, Banda HT, Gondwe M, et al. Non-typhoidal salmonella bacteraemia among HIV-infected Malawian adults: high mortality and frequent recrudescence. AIDS 2002; 16:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31542/abstract/9\">",
"      Gordon MA, Graham SM, Walsh AL, et al. Epidemics of invasive Salmonella enterica serovar enteritidis and S. enterica Serovar typhimurium infection associated with multidrug resistance among adults and children in Malawi. Clin Infect Dis 2008; 46:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31542/abstract/10\">",
"      Kariuki S, Revathi G, Kariuki N, et al. Characterisation of community acquired non-typhoidal Salmonella from bacteraemia and diarrhoeal infections in children admitted to hospital in Nairobi, Kenya. BMC Microbiol 2006; 6:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31542/abstract/11\">",
"      Kariuki S, Revathi G, Kariuki N, et al. Invasive multidrug-resistant non-typhoidal Salmonella infections in Africa: zoonotic or anthroponotic transmission? J Med Microbiol 2006; 55:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31542/abstract/12\">",
"      Siga&uacute;que B, Roca A, Mandomando I, et al. Community-acquired bacteremia among children admitted to a rural hospital in Mozambique. Pediatr Infect Dis J 2009; 28:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31542/abstract/13\">",
"      Zaidi E, Bachur R, Harper M. Non-typhi Salmonella bacteremia in children. Pediatr Infect Dis J 1999; 18:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31542/abstract/14\">",
"      Shimoni Z, Pitlik S, Leibovici L, et al. Nontyphoid Salmonella bacteremia: age-related differences in clinical presentation, bacteriology, and outcome. Clin Infect Dis 1999; 28:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31542/abstract/15\">",
"      Jones TF, Ingram LA, Cieslak PR, et al. Salmonellosis outcomes differ substantially by serotype. J Infect Dis 2008; 198:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31542/abstract/16\">",
"      Rodr&iacute;guez M, de Diego I, Mart&iacute;nez N, et al. Nontyphoidal Salmonella causing focal infections in patients admitted at a Spanish general hospital during an 11-year period (1991-2001). Int J Med Microbiol 2006; 296:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31542/abstract/17\">",
"      Ramos JM, Aguado JM, Garc&iacute;a-Corbeira P, et al. Clinical spectrum of urinary tract infections due on nontyphoidal Salmonella species. Clin Infect Dis 1996; 23:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31542/abstract/18\">",
"      Sirinavin S, Chiemchanya S, Vorachit M. Systemic nontyphoidal Salmonella infection in normal infants in Thailand. Pediatr Infect Dis J 2001; 20:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31542/abstract/19\">",
"      Molyneux EM, Mankhambo LA, Phiri A, et al. The outcome of non-typhoidal salmonella meningitis in Malawian children, 1997-2006. Ann Trop Paediatr 2009; 29:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31542/abstract/20\">",
"      Cohen PS, O'Brien TF, Schoenbaum SC, Medeiros AA. The risk of endothelial infection in adults with salmonella bacteremia. Ann Intern Med 1978; 89:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31542/abstract/21\">",
"      Benenson S, Raveh D, Schlesinger Y, et al. The risk of vascular infection in adult patients with nontyphi Salmonella bacteremia. Am J Med 2001; 110:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31542/abstract/22\">",
"      Hsu RB, Lin FY. Risk factors for bacteraemia and endovascular infection due to non-typhoid salmonella: a reappraisal. QJM 2005; 98:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31542/abstract/23\">",
"      Oskoui R, Davis WA, Gomes MN. Salmonella aortitis. A report of a successfully treated case with a comprehensive review of the literature. Arch Intern Med 1993; 153:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31542/abstract/24\">",
"      Chen PL, Chang CM, Wu CJ, et al. Extraintestinal focal infections in adults with nontyphoid Salmonella bacteraemia: predisposing factors and clinical outcome. J Intern Med 2007; 261:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31542/abstract/25\">",
"      Burkhardt JE, Walterspiel JN, Schaad UB. Quinolone arthropathy in animals versus children. Clin Infect Dis 1997; 25:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31542/abstract/26\">",
"      Leibovitz E. The use of fluoroquinolones in children. Curr Opin Pediatr 2006; 18:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31542/abstract/27\">",
"      Stevenson JE, Gay K, Barrett TJ, et al. Increase in nalidixic acid resistance among non-Typhi Salmonella enterica isolates in the United States from 1996 to 2003. Antimicrob Agents Chemother 2007; 51:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31542/abstract/28\">",
"      Humphries RM, Fang FC, Aarestrup FM, Hindler JA. In vitro susceptibility testing of fluoroquinolone activity against Salmonella: recent changes to CLSI standards. Clin Infect Dis 2012; 55:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31542/abstract/29\">",
"      Lee HY, Su LH, Tsai MH, et al. High rate of reduced susceptibility to ciprofloxacin and ceftriaxone among nontyphoid Salmonella clinical isolates in Asia. Antimicrob Agents Chemother 2009; 53:2696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31542/abstract/30\">",
"      Jean SS, Lee YT, Guo SM, Hsueh PR. Recurrent infections caused by cefotaxime- and ciprofloxacin-resistant Salmonella enterica serotype choleraesuis treated successfully with imipenem. J Infect 2005; 51:e163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31542/abstract/31\">",
"      Li WC, Huang FY, Liu CP, et al. Ceftriaxone resistance of nontyphoidal Salmonella enterica isolates in Northern Taiwan attributable to production of CTX-M-14 and CMY-2 beta-lactamases. J Clin Microbiol 2005; 43:3237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31542/abstract/32\">",
"      Miriagou V, Tzouvelekis LS, Rossiter S, et al. Imipenem resistance in a Salmonella clinical strain due to plasmid-mediated class A carbapenemase KPC-2. Antimicrob Agents Chemother 2003; 47:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31542/abstract/33\">",
"      Hsu RB, Lin FY. Nontyphoid Salmonella infection in heart transplant recipients. Am J Med Sci 2008; 336:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31542/abstract/34\">",
"      Dhar JM, al-Khader AA, al-Sulaiman M, al-Hasani MK. Non-typhoid Salmonella in renal transplant recipients: a report of twenty cases and review of the literature. Q J Med 1991; 78:235.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3126 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-23B01FB2C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_51_31542=[""].join("\n");
var outline_f30_51_31542=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MICROBIOLOGY AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Extraintestinal focal infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Endovascular infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Antibiotic selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Bacteremia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Extraintestinal focal infections and endovascular infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/8/26761?source=related_link\">",
"      Approach to the patient with nontyphoidal Salmonella in a stool culture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/20/25930?source=related_link\">",
"      Diagnosis and treatment of gram-negative bacillary meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/2/42024?source=related_link\">",
"      Epidemiology, microbiology, clinical manifestations, and diagnosis of typhoid fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/60/28618?source=related_link\">",
"      Fluoroquinolones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/19/14649?source=related_link\">",
"      Microbiology and epidemiology of salmonellosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/37/19033?source=related_link\">",
"      Pathogenesis of Salmonella gastroenteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/31/27122?source=related_link\">",
"      Patient information: Salmonellosis (Salmonella) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/58/18345?source=related_link\">",
"      Treatment and prevention of typhoid fever",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_51_31543="Dermatologic procedures";
var content_f30_51_31543=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Dermatologic procedures",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/51/31543/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/51/31543/contributors\">",
"     Beth G Goldstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/51/31543/contributors\">",
"     Adam O Goldstein, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/51/31543/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/51/31543/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/51/31543/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/51/31543/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/51/31543/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dermatologic procedures can be utilized to confirm a suspected diagnosis (eg, scabies preparation), to differentiate between two diagnoses (eg, potassium hydroxide (KOH) preparation to differentiate between fungal infection and dermatitis), and to give a definitive treatment for common dermatoses (eg, cryosurgery for actinic keratoses).",
"   </p>",
"   <p>",
"    A number of dermatologic procedures will be described here. Dermoscopy, skin biopsy, and intralesional injection are discussed separately.",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/57/38807?source=see_link\">",
"     \"Overview of dermoscopy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/11/13497?source=see_link\">",
"     \"Dermoscopic evaluation of skin lesions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40264?source=see_link\">",
"     \"Skin biopsy techniques\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/45/40660?source=see_link\">",
"     \"Intralesional injection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is essential to have the proper equipment before starting any procedure. In addition, the benefits of good lighting cannot be overstated. Occasionally, the use of a magnifying hand lens (or a special magnifying lens system, such as dermoscopy) is helpful for delineating the types of lesions present and deciding where to perform a procedure.",
"   </p>",
"   <p>",
"    Rushing a dermatologic procedure is helpful to neither the patient nor to the physician and may result in a poor outcome. If the patient is scheduled specifically for cutaneous surgery, suggested preoperative guidelines are useful:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ask about allergies and past reactions to local anesthetics.",
"     </li>",
"     <li>",
"      Ask whether the patient has a pacemaker (may want to avoid electrocautery near a pacemaker).",
"     </li>",
"     <li>",
"      Ask about a history of a bleeding diathesis; if the patient has not previously undergone a procedure, ask about a family history of bleeding diatheses.",
"     </li>",
"     <li>",
"      Discontinue nonsteroidal antiinflammatory drugs for two to three days before surgery, substituting",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      if necessary. Vitamin E and some herbal agents, such as ginkgo, can also prolong bleeding times and should be avoided before surgery.",
"     </li>",
"     <li>",
"      For most patients, the risk of thrombotic events from discontinuing antithrombotic agents (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      ) outweighs any increased risk of bleeding with their continued administration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/51/31543/abstract/1,2\">",
"       1,2",
"      </a>",
"      ]. Ice packs on the day of surgery may help minimize local bleeding. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Wound care'",
"      </a>",
"      below.) Patients who are taking aspirin for primary prevention of cardiovascular disease or for an indication other than antiplatelet therapy (such as pain control), should discontinue aspirin 7 to 10 days before surgery. In patients receiving ongoing warfarin therapy, it is important to maintain the INR within the therapeutic range to ensure that the patient is not overanticoagulated prior to surgery. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/50/35626?source=see_link&amp;anchor=H10#H10\">",
"       \"Management of anticoagulation before and after elective surgery\", section on 'Dental or excisional cutaneous procedures'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Avoid alcoholic beverages for 48 hours before surgery; they also may increase bleeding.",
"     </li>",
"     <li>",
"      If the procedure is taking place near the eye or in a location that would make it difficult to drive safely, the patient should bring along someone to drive home.",
"     </li>",
"     <li>",
"      If the procedure is taking place on the head, it is advisable to wear a button-up shirt so that a shirt does not have to be pulled back on over the dressing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When performing procedures such as cryosurgery, biopsies, and excisions, it is important to inform patients of potential side effects, such as scarring, bleeding, infection, recurrence, and the possible need for further treatment, and document this education appropriately in the medical record. Also inform patients of potential side effects if nerves that commonly run in the superficial cutis are severed: surgery in the region of the temple can lead to permanent eyelid drooping; surgery at Erb's point in the neck can lead to scapular winging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4044225\">",
"    <span class=\"h1\">",
"     WOOD'S LAMP EXAMINATION (BLACK LIGHT)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A Wood's lamp examination is used to aid in the diagnosis of tinea capitis, erythrasma, and porphyria cutanea tarda. Certain specimens will fluoresce when examined under a Wood's lamp.",
"   </p>",
"   <p>",
"    Tinea capitis due to Microsporum canis or Microsporum audouinii fluoresce blue-green under Wood's lamp, but these species cause less than 20 percent of tinea capitis in the United States; thus, negative Wood's lamp findings on the scalp do not rule out this diagnosis. In erythrasma, the bacterium causing the inguinal scaling eruption, Corynebacterium minutissimum, produces a compound that fluoresces coral-red under a Wood's lamp. A presumptive diagnosis of porphyria cutanea tarda is possible if pink or orange-red fluorescence is seen in urine examined under a Wood's light. A Wood's light can also be used to better define the borders of a pigmented lesion to ensure complete excision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4044232\">",
"    <span class=\"h2\">",
"     Equipment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Wood's light",
"     </li>",
"     <li>",
"      Electrical source",
"     </li>",
"     <li>",
"      Darkened room",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4044239\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Examine the specimen under the Wood's lamp in a darkened room to optimally observe any fluorescence",
"     </li>",
"     <li>",
"      If the patient has recently bathed, fluorescence may be minimal",
"     </li>",
"     <li>",
"      Fibers, scale, and clothing also may fluoresce",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4044329\">",
"    <span class=\"h1\">",
"     DERMOSCOPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principles of dermoscopy and dermoscopic examination of cutaneous lesions are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/57/38807?source=see_link\">",
"     \"Overview of dermoscopy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/11/13497?source=see_link\">",
"     \"Dermoscopic evaluation of skin lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4044416\">",
"    <span class=\"h1\">",
"     POTASSIUM HYDROXIDE (KOH) PREP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potassium hydroxide (KOH) can be used to microscopically identify fungus or yeast from epidermal skin scrapings. KOH dissolves epidermal keratinocytes, allowing for easier demonstration and identification of organisms. KOH prep is indicated to identify fungal infections (eg, tinea pedis, manus, corporis, cruris, capitis; onychomycosis) and yeast infections (eg, tinea versicolor, candidiasis). KOH examination may yield false negative results in 12 to 24 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31543/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4044423\">",
"    <span class=\"h2\">",
"     Equipment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Alcohol preparations",
"     </li>",
"     <li>",
"      No. 15 blade or glass slide for scraping",
"     </li>",
"     <li>",
"      Glass slide and coverslip",
"     </li>",
"     <li>",
"      KOH 10% to 20% solution with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/22/33123?source=see_link\">",
"       dimethylsulfoxide",
"      </a>",
"      (DMSO); heating is not needed if DMSO is used",
"     </li>",
"     <li>",
"      Alcohol lamp",
"     </li>",
"     <li>",
"      Microscope",
"     </li>",
"     <li>",
"      Hemostats or 2x2 gauze for scalp lesions; tongue blade for oral lesions; nail clippers for nail lesions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4044430\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clean the skin of any lotions or creams with an alcohol preparation.",
"     </li>",
"     <li>",
"      Obtain a specimen. For the skin, use either a no. 15 blade or the side of a glass slide to scrape material loose from a leading edge; if there are pustules or vesicles, scrape the roof onto a glass slide. For oral candidiasis, use a tongue blade to scrape white plaques onto a slide. For nail infections, remove as much nail as possible with nail clippers to expose the most proximally involved area, then scrape the subungual debris onto a slide with a 1 to 2 mm curette or a no. 15 blade. For hair infections, pluck five to ten hairs from an active scaling area with a hemostat and place them on a slide, or rub a 2x2 gauze vigorously to an area of alopecia and scaling, placing the broken-off hairs onto a glass slide.",
"     </li>",
"     <li>",
"      Apply two or three drops KOH to the slide, then apply the coverslip.",
"     </li>",
"     <li>",
"      If KOH without DMSO is used, heat the slide gently over an alcohol lamp or with a lighter for two or three seconds until just before it just starts to boil. This will hasten the breakdown of cell wall components and make it easier to see fungal remnants.",
"     </li>",
"     <li>",
"      Examine at 10 times magnification, using the lowest light possible (lowering the condenser is helpful). Examine at 40 times magnification if necessary to confirm the presence of hyphae in dermatophyte infections and pseudohyphae or yeast forms for Candida or Pityrosporum infections (",
"      <a class=\"graphic graphic_picture graphicRef60102 graphicRef79879 graphicRef58965 \" href=\"mobipreview.htm?21/31/22010\">",
"       picture 1A-C",
"      </a>",
"      ). Use the fine focus to demonstrate refractile properties of organisms compared with epidermal cell walls.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For nail specimens, if the KOH with DMSO does not show the organism, you can allow the preparation to sit for several hours, then reexamine. This helps the thick keratin dissolve and aids in examination of fungal elements",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     FUNGAL CULTURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fungal cultures are especially useful in hair or nail infections, because the KOH test results are not helpful in identifying the fungal species or differentiating fungal from yeast or mold infections. This differentiation can influence therapy. As an example, nail infections due to molds will not respond to oral therapies but may respond to nail removal. In contrast, fungal cultures are rarely needed to diagnose fungal or yeast infections of the skin. Fungal cultures may yield false negative results in over 40 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31543/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Equipment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Alcohol preparation",
"     </li>",
"     <li>",
"      No. 15 blade or glass slide for scraping",
"     </li>",
"     <li>",
"      Glass slide and coverslip",
"     </li>",
"     <li>",
"      Alcohol lamp",
"     </li>",
"     <li>",
"      Microscope",
"     </li>",
"     <li>",
"      Hemostats or gauze for scalp lesions; tongue blade for oral lesions; nail clippers for nail lesions",
"     </li>",
"     <li>",
"      Dermatophyte Test Medium (Troy Biologicals, Inc., Troy, Mich.) for cultures",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obtain a specimen. For hair",
"      <strong>",
"       :",
"      </strong>",
"      remove five to ten hairs from an involved, scaling area with one quick motion using a hemostat, or rub a 2x2 gauze vigorously to an area of alopecia and scaling, placing the broken off hairs into the media. After placing the hairs in the culture medium, loosely recap the bottle and store it in a dark cabinet. For nails",
"      <strong>",
"       :",
"      </strong>",
"      remove a portion of the involved nail with nail clippers to expose the most proximal involved area. Using a no. 15 blade or a curette, scrape the proximal subungual debris into the culture medium. Nail clippers can be used to remove the involved proximal areas, but cover the nail with 4x4 gauze to avoid having a specimen fly across the room. After embedding some of the specimen in the medium, apply the cap loosely and store in a dark cabinet.",
"     </li>",
"     <li>",
"      Examine the specimen every two weeks for four to eight weeks, looking for the phenol indicator in the test medium to turn from yellow to red.",
"     </li>",
"     <li>",
"      Monomorphous colony growth indicates a dermatophyte infection. Yeast looks like creamy, discrete colonies (",
"      <a class=\"graphic graphic_picture graphicRef50344 \" href=\"mobipreview.htm?40/12/41167\">",
"       picture 2",
"      </a>",
"      ). Bacterial contaminants and nonpathogenic molds also can grow; it may be necessary to send the specimen to a mycology laboratory if the diagnosis is in doubt.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TZANCK SMEAR",
"    </span>",
"    &nbsp;&mdash;&nbsp;A Tzanck smear is used to aid in diagnosis of infection with the Herpes virus, including herpes simplex, varicella, and zoster. Tzanck smears are performed less commonly than in the past because of the availability of immunofluorescence tests for these agents. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40265?source=see_link&amp;anchor=H27#H27\">",
"     \"Clinical manifestations and diagnosis of herpes simplex virus type 1 infection\", section on 'Immunofluorescence staining'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Equipment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Alcohol preparation",
"     </li>",
"     <li>",
"      No. 15 blade",
"     </li>",
"     <li>",
"      Cotton swab",
"     </li>",
"     <li>",
"      Glass slide and coverslip",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13316?source=see_link\">",
"       Mineral oil",
"      </a>",
"     </li>",
"     <li>",
"      Microscope",
"     </li>",
"     <li>",
"      For modified quick Tzanck: Cyto Prep spray fixative and Sedi Stain",
"     </li>",
"     <li>",
"      For routine staining: 95 percent methanol, distilled water, and Giemsa, Wright's, or Hansel stain",
"     </li>",
"     <li>",
"      Diff-Quick Stain Set (American Scientific Products, McGaw Park, Ill.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clean an area with an intact vesicle for best results. If no intact vesicles are present, use the edge of the most recently appearing erosion or ulcer.",
"     </li>",
"     <li>",
"      Remove a blister roof with a no. 15 blade, blot any excess blister fluid, then scrape the base of the vesicle, erosion, or ulcer with the scalpel blade, spreading a thin layer of the resultant material onto a glass slide.",
"     </li>",
"     <li>",
"      For a modified Tzanck test, immediately fix the slide with Cyto Prep, and air dry for 5 to 10 minutes. Flood the slide with Sedi-Stain for 30 to 60 seconds, rinse gently with tap water, and air dry. The modified test is easier, quicker, and utilizes fewer supplies than the traditional test.",
"     </li>",
"     <li>",
"      For routine staining, fix the specimen by flooding the slide with 95 percent methanol for 5 seconds, then air dry for 1 to 2 minutes. Flood the slide with nuclear stain (Wright's, Giemsa, or Hansel stain) for 30 to 60 seconds. Add distilled water to the slide for 30 seconds, then flood it with distilled water to remove any remaining stain. Flood the slide again with 95 percent methanol for Hansel stain. Air dry without blotting.",
"     </li>",
"     <li>",
"      Diff-Quick will stain in less than one minute, but unless several Tzanck smears are done every week, the expense to maintain a prepared set may not be worthwhile because of evaporation.",
"     </li>",
"     <li>",
"      Observe the slide initially at 40 times magnification to find areas where individual cells are best identified, that is, not clumped together. Then use oil immersion to identify multinucleated giant cells, where nuclei are molded together in giant epithelial cells. Using microscope settings under high light and with the condenser up is most helpful.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4044140\">",
"    <span class=\"h1\">",
"     TOPICAL ANESTHESIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Choosing an appropriate anesthetic agent is an important consideration for many dermatologic procedures. The choice of an anesthetic agent depends upon the type of procedure, the age and personality of the patient, the skill of the clinician, and the properties of the agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4044147\">",
"    <span class=\"h2\">",
"     Ice or ethyl chloride",
"    </span>",
"    &nbsp;&mdash;&nbsp;These topical agents are effective for superficial anesthesia of short (&lt;5 seconds) duration (eg, before snip excision of an acrochordon [skin tag]). These modalities may also be useful to lessen the pain of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    injection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4044154\">",
"    <span class=\"h2\">",
"     Topical lidocaine preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    preparations have been used for dermatologic procedures.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       Lidocaine",
"      </a>",
"      <strong>",
"       , 1 percent, without epinephrine",
"      </strong>",
"      &minus; Lidocaine without epinephrine is particularly useful for procedures requiring anesthesia of the fingers, toes, nose, penis, or ear. For most dermatologic procedures, inject 1 to 5 mL (maximum 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      = 28 mL for a 70 kg person) into the lesion. The standard solution of lidocaine has a pH of 5.0 to 7.0. It can be buffered to a pH of 7.0 to 7.2 by adding one part of 1",
"      <span class=\"nowrap\">",
"       mEq/mL",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      to 9 or 10 parts of 1 percent lidocaine to decrease the discomfort associated with injection and to enhance anesthetic tissue dispersion. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33689?source=see_link\">",
"       \"Infiltration of local anesthetics\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       Lidocaine",
"      </a>",
"      <strong>",
"       , 1 percent, with epinephrine 1:100,000",
"      </strong>",
"      &minus; This is particularly useful for anesthesia in all procedures except those that involve the fingers, toes, nose, penis or earlobes or in patients on non-selective beta-blockers. The addition of epinephrine produces vasoconstriction that cuts down substantially on local bleeding. The vasoconstriction prolongs anesthetic action by keeping the solution in local tissues for longer periods; this also allows for larger volumes of anesthetic to be used safely (maximum 7",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      = 49 cc for 70 kg person). Lidocaine with epinephrine may also be buffered as discussed above.",
"      <br/>",
"      <br/>",
"      The vasoconstrictive effects of epinephrine may not be adequate immediately after administration. We typically inject the agent, complete the preparation of the area, and wait approximately 15 to 20 minutes after injection before initiating surgical excisions. We generally do not wait after injection to perform smaller shave or punch procedures.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       Lidocaine",
"      </a>",
"      <strong>",
"       2.5 percent and",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/32/6660?source=see_link\">",
"       prilocaine",
"      </a>",
"      <strong>",
"       2.5 percent cream (EMLA, 5 g, 30 g)",
"      </strong>",
"      &minus;",
"      <strong>",
"      </strong>",
"      EMLA is a cream that is applied generously to the affected area (not rubbed in). The area is then occluded with plastic wrap for 1.5 to 2 hours before the scheduled procedure. The cream is an effective method for providing anesthesia for scheduled procedures in infants and children, for those with a needle phobia, or for superficial procedures such as shave or Gradle scissor excisions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4044161\">",
"    <span class=\"h2\">",
"     0.9 percent normal saline",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal saline containing benzyl alcohol as a preservative (called bacteriostatic saline) can act as a superficial anesthetic agent. The advantage over",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    is that normal saline does not cause initial burning on injection. Normal saline is a useful anesthetic agent for superficial procedures that do not require suturing such as superficial shave or Gradle scissor excisions, or to give more painless anesthesia prior to lidocaine injection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4044168\">",
"    <span class=\"h2\">",
"     Combinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some patients, combinations of the above anesthetics are useful. As an example, when performing an excisional or punch biopsy, after a patient has applied the",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"      lidocaine",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?6/32/6660?source=see_link\">",
"      prilocaine",
"     </a>",
"    </span>",
"    cream for two hours the clinician can infiltrate the area with 0.9 percent normal saline and then inject 1 percent lidocaine with epinephrine, giving excellent overall anesthesia for the procedure but with little to no discomfort. Drawbacks to this kind of approach include the amount of patient education and advance preparation time needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SKIN BIOPSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin biopsy is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40264?source=see_link\">",
"     \"Skin biopsy techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4044550\">",
"    <span class=\"h1\">",
"     INTRALESIONAL INJECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications and techniques of intralesional injection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/45/40660?source=see_link\">",
"     \"Intralesional injection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     CRYOSURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryosurgery is used to rapidly, safely, and effectively treat many common skin lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31543/abstract/6\">",
"     6",
"    </a>",
"    ]. Liquid nitrogen is the cryogen of choice. Cellular destruction occurs secondarily to ice crystal formation, cellular dehydration, and subsequent protein and enzymatic denaturization. Destruction is more pronounced with rapid freezing and slow thawing cycles.",
"   </p>",
"   <p>",
"    Cryosurgery is typically used for removal of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Benign lesions (eg, warts, seborrheic keratoses)",
"     </li>",
"     <li>",
"      Premalignant lesions (eg, actinic keratoses)",
"     </li>",
"     <li>",
"      Rarely malignant skin tumors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A cotton swab, spray, or probe may be used to apply liquid nitrogen. The cotton swab results in less depth of freezing, but is usually adequate for most benign lesions. A new swab must be used with each dip into the liquid nitrogen reservoir.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Equipment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Storage tank",
"     </li>",
"     <li>",
"      Liquid nitrogen",
"     </li>",
"     <li>",
"      Thermos bottle with hole in lid and cotton-tipped swab, or cryosurgery tank and gun (eg, Cry-Ac Spray, www.brymill.com)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Local anesthesia is usually not necessary, although is recommended for very large lesions.",
"     </li>",
"     <li>",
"      It is always better to underfreeze than to overfreeze a lesion, to prevent complications; more can be frozen at a later date, if necessary.",
"     </li>",
"     <li>",
"      Frozen areas of the skin will turn white immediately. This is referred to as the \"freeze ball'' or \"iceball.'' The depth of freeze should be roughly equal to one and one-half times the radius of the freeze ball unless the lesion is superficial, eg, solar lentigo, in which the depth of freeze is less.",
"     </li>",
"     <li>",
"      To treat small papules or thin, flat lesions, freeze the lesion for 5 to 10 seconds, leaving a rim of white 1 to 3 mm around the lesion.",
"     </li>",
"     <li>",
"      For thicker warts or seborrheic keratoses, freeze for up to 40 seconds. This does not mean that the liquid nitrogen should be applied for 40 seconds, but that the \"iceball'' should be maintained for 40 seconds. Repeat applications may be necessary for thicker lesions, waiting until the lesion completely thaws (usually about 2 to 40 seconds) before refreezing.",
"     </li>",
"     <li>",
"      Often the skin will quickly become edematous and \"urticarial,'' because freezing causes separation of the epidermis from the dermis, with resultant blister formation. A hemorrhagic area may develop if the lesion is frozen deeper than the epidermis. Warn patients that their eyelid may be quite swollen if there is cryotherapy done nearby. Any rings should be removed if cryotherapy is performed to the digit.",
"     </li>",
"     <li>",
"      Liquid nitrogen often provides adequate anesthesia when using a curette to remove lesions. This therapy is particularly useful for warts, acrochordons, or seborrheic keratoses, because often patients want the lesion removed before they leave the office. Subsequent use of aluminum chloride for hemostasis, applied with a cotton swab, is often necessary when lesions are removed in this manner.",
"     </li>",
"     <li>",
"      Treatment of a malignant tumor should be performed with a thermocouple, which allows for the temperature of the lesion to be monitored during treatment to ensure adequate temperature for tumor necrosis. Local anesthesia with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      1 percent usually is required. Cryotherapy for tumor control, while rarely done in the United States, has comparable success rates to surgical approaches in appropriately trained hands.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryotherapy may be associated with a number of short and long-term complications. Short-term complications include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pain is variable among individuals; however, be prepared for vasovagal reactions and do not use cryotherapy in small children. Lesions may be painful after freezing as a result of pressure from edema caused by the blister. Advise patients to use a sterile lancet and \"pop'' the blister if this occurs.",
"     </li>",
"     <li>",
"      Hemorrhage is common. Inform patients that formation of a \"blood blister'' is normal, especially when treating thick lesions such as warts.",
"     </li>",
"     <li>",
"      Infection is possible. Educate patients on proper wound care with dilute",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/41/41617?source=see_link\">",
"       hydrogen peroxide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/20/6469?source=see_link\">",
"       bacitracin",
"      </a>",
"      or Polysporin until healing occurs.",
"     </li>",
"     <li>",
"      Pyogenic granuloma occurs rarely with healing. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/34/553?source=see_link\">",
"       \"Overview of benign lesions of the skin\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Long-term complications of cryotherapy include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nerve damage is the most serious complication, and is especially likely where nerves are superficial, such as on the sides of fingers, postauricular, or the peroneal nerve.",
"     </li>",
"     <li>",
"      Pigmentary changes are common and may be especially disfiguring in black patients.",
"     </li>",
"     <li>",
"      Hypertrophic scar formation and tissue defects with delayed healing are possible if lesions are frozen too deeply or when freezing thick lesions.",
"     </li>",
"     <li>",
"      Permanent nail dystrophy may occur if a periungual lesion is frozen too deeply.",
"     </li>",
"     <li>",
"      Recurrence of a lesion, particularly warts, is possible.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     CURETTAGE AND ELECTRODESICCATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Curettage and electrodesiccation is used to remove",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    destroy skin tumors using a curette and electrical current to the affected area. The technique does not provide the best tissue sampling for pathologic diagnosis; if carcinoma is a strong consideration, perform a small shave biopsy before curettage to provide the pathologist with adequate architecture for diagnosis. While curettage and electrodesiccation may be useful therapy for small skin tumors, such as superficial basal or squamous cell carcinoma, primary excisional approaches are often preferred to achieve maximum cure rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31543/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Curettage and electrodesiccation are indicated for removal of benign lesions (eg, warts, seborrheic keratoses, pyogenic granuloma, acrochordons) and malignant lesions (eg, basal cell and squamous cell carcinomas, including squamous cell carcinoma in situ [Bowen's disease] and keratoacanthomas). Avoid tumors that are fibrotic, scar-like (morpheaform), or located in areas of embryonic fusion lines (eg, nasolabial folds, inner canthal region, posterior auricular folds). Lesions extending into the subcutaneous fat also should be removed by other means (eg, excision).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Equipment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Gloves, goggles, and mask",
"     </li>",
"     <li>",
"      Alcohol prep, cotton swabs, and 4x4 gauze",
"     </li>",
"     <li>",
"      Anesthesia: local anesthetic with 30-gauge needle",
"     </li>",
"     <li>",
"      Aluminum chloride",
"     </li>",
"     <li>",
"      Curettes: sizes 1 to 7 mm",
"     </li>",
"     <li>",
"      Electrosurgical electrodesiccation instrument (eg, Hyfrecator,",
"      <span class=\"nowrap\">",
"       www.conmed.com/products_electro_generatorTOC.php)",
"      </span>",
"     </li>",
"     <li>",
"      Antibiotic ointment",
"     </li>",
"     <li>",
"      Telfa dressing and surgical tape",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For benign lesions, curettage and electrodesiccation are performed superficially, while for malignant lesions the techniques are used more aggressively to destroy more tumor tissue. A small acrochordon may be quickly electrodesiccated, and the curette can then be used to simply scrape off the char.",
"     </li>",
"     <li>",
"      Wipe the area(s) to be treated with an alcohol prep, thoroughly dry it, and mark the site with a surgical marking pen if the lesion tends to \"disappear'' with anesthesia.",
"     </li>",
"     <li>",
"      Anesthetize the area.",
"     </li>",
"     <li>",
"      The smaller the lesion, the smaller should be the curette; 3, 4, and 5 mm curettes are used most commonly.",
"     </li>",
"     <li>",
"      Using the sharp side of the curette, scrape the base of the lesion. When treating a carcinoma, scrape the base in several different directions until the underlying tissue feels firm. Cancer cells are not very adhesive and will feel \"mushy.''",
"     </li>",
"     <li>",
"      Electrodesiccate the area. Most instruments will work only in a dry field. If necessary, apply aluminum chloride to the area using a cotton swab, rolling it very slowly to dry the area.",
"     </li>",
"     <li>",
"      Benign lesions require only one treatment, while malignant lesions should be curetted and desiccated three times.",
"     </li>",
"     <li>",
"      After obtaining hemostasis, apply antibiotic ointment and a dressing. A pressure dressing may be required.",
"     </li>",
"     <li>",
"      Educate patients about wound care. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Wound care'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential complications of curettage and electrodesiccation include scar, lesion recurrence, infection, insufficient tissue sample, and, rarely, vital structure damage. Avoid curettage and electrodesiccation for lesions on the soles of the feet if other, less scarring modalities are available. Avoid electrodessication in patients with defibrillators or certain types of pacemakers. Electrocautery should be used in patients with these devices if needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     CYST EXCISION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyst excision is indicated for the removal of cystic lesions (eg, epidermal inclusion cyst).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Equipment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Alcohol prep, 4x4 gauze, and cotton swabs",
"     </li>",
"     <li>",
"      Surgical marking pen",
"     </li>",
"     <li>",
"      Local anesthetic using a 30-gauge needle",
"     </li>",
"     <li>",
"      Hibiclens or equivalent preparation to sterilize skin surface",
"     </li>",
"     <li>",
"      Two sterile towels and towel clamps or a disposable drape",
"     </li>",
"     <li>",
"      Sterile gloves",
"     </li>",
"     <li>",
"      Needle holders of appropriate size for suture needle",
"     </li>",
"     <li>",
"      Iris scissors, curved",
"     </li>",
"     <li>",
"      Adson forceps",
"     </li>",
"     <li>",
"      Hemostats",
"     </li>",
"     <li>",
"      Skin hooks",
"     </li>",
"     <li>",
"      Sutures (5-0 or 6-0 nonabsorbable ethilon or prolene for the face, 4-0 nonabsorbable ethilon or prolene for the trunk, 3-0 or 4-0 nonabsorbable ethilon or prolene for the extremities)",
"     </li>",
"     <li>",
"      Electrocoagulation unit",
"     </li>",
"     <li>",
"      Formalin",
"     </li>",
"     <li>",
"      Antibiotic ointment and adhesive bandage",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Define the best closure lines to coincide with least tension on the final wound.",
"     </li>",
"     <li>",
"      Clean the skin site with an alcohol prep and mark the area to be excised.",
"     </li>",
"     <li>",
"      Anesthetize the area.",
"     </li>",
"     <li>",
"      Stabilize the skin with one hand by stretching it in three-point traction, using pressure at three sites.",
"     </li>",
"     <li>",
"      Excise the ellipse with a no. 15 scalpel, carrying the excision into the superficial dermis only. If the lesion is very small, a punch may be used to remove the superficial skin, taking great care not to incise the cyst itself. Many cysts are very superficial.",
"     </li>",
"     <li>",
"      Using forceps, grasp one end of the ellipse or punch, and with a curved iris scissors gently work into the dermis surrounding the cyst to shell it out. Continue shelling it out in all directions, taking care to avoid rupture.",
"     </li>",
"     <li>",
"      Obtain hemostasis with either electrocoagulation or by tying off any bleeding vessels.",
"     </li>",
"     <li>",
"      Close the wound in a layered fashion if there is any significant dead space. Layered closure also is important if significant stress is placed on the wound.",
"     </li>",
"     <li>",
"      Apply antibiotic ointment and a pressure dressing.",
"     </li>",
"     <li>",
"      Remove sutures (4 to 7 days for the face, 7 to 14 days for the trunk, extremities, or scalp).",
"     </li>",
"     <li>",
"      Educate patients about wound care. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Wound care'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     WOUND CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proper wound care is essential after performing some dermatologic procedures. Advise patients of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Leave the initial dressing on for 24 hours; replace if it gets wet.",
"     </li>",
"     <li>",
"      Clean the wound daily with dilute",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/41/41617?source=see_link\">",
"       hydrogen peroxide",
"      </a>",
"      . Mix",
"      <span class=\"nowrap\">",
"       1/2",
"      </span>",
"      tap water with",
"      <span class=\"nowrap\">",
"       1/2",
"      </span>",
"      hydrogen peroxide. Use a cotton-tipped swab to remove dried blood or crust.",
"     </li>",
"     <li>",
"      Dry the wound gently with a piece of gauze.",
"     </li>",
"     <li>",
"      Apply a thin layer of petrolatum or an antibiotic ointment such as polysporin or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/20/6469?source=see_link\">",
"       bacitracin",
"      </a>",
"      for high risk areas such as the distal extremities, or in high risk patients such as diabetics.",
"     </li>",
"     <li>",
"      Apply a nonstick bandage such as Telfa or a Band-Aid. Tape into place with nonallergenic tape.",
"     </li>",
"     <li>",
"      If bleeding occurs, put an ice pack on the wound for 20 minutes with firm pressure.",
"     </li>",
"     <li>",
"      Use",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      rather than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      for pain.",
"     </li>",
"     <li>",
"      Return to the office if wound erythema increases or there is increased pain or pus from the wound.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4330984\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dermatologic procedures are commonly performed to confirm a suspected diagnosis, differentiate between two diagnoses, or provide a definitive treatment for common dermatoses.",
"     </li>",
"     <li>",
"      Good lighting and the use of a magnifying hand lens or a dermatoscope are helpful for evaluating the lesions and deciding where to perform a procedure.",
"     </li>",
"     <li>",
"      A proper preoperative evaluation of the patient is necessary before a surgical procedure, including medical and medication history, patient information about potential side effects, recurrence, and the possible need for further treatment. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnostic procedures routinely performed in the dermatologist office include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Wood&rsquo;s lamp examination",
"     </li>",
"     <li>",
"      Dermoscopy (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/57/38807?source=see_link\">",
"       \"Overview of dermoscopy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/11/13497?source=see_link\">",
"       \"Dermoscopic evaluation of skin lesions\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Potassium hydroxide (KOH) prep (",
"      <a class=\"graphic graphic_picture graphicRef60102 graphicRef79879 graphicRef58965 \" href=\"mobipreview.htm?21/31/22010\">",
"       picture 1A-C",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Fungal culture (",
"      <a class=\"graphic graphic_picture graphicRef50344 \" href=\"mobipreview.htm?40/12/41167\">",
"       picture 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Tzanck smear",
"     </li>",
"     <li>",
"      Skin biopsy (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40264?source=see_link\">",
"       \"Skin biopsy techniques\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Procedures to treat common skin diseases include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Intralesional injection (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/45/40660?source=see_link\">",
"       \"Intralesional injection\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cryosurgery",
"     </li>",
"     <li>",
"      Curettage and electrodessication",
"     </li>",
"     <li>",
"      Cyst excision",
"     </li>",
"     <li>",
"      Wound care",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31543/abstract/1\">",
"      Kovich O, Otley CC. Thrombotic complications related to discontinuation of warfarin and aspirin therapy perioperatively for cutaneous operation. J Am Acad Dermatol 2003; 48:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31543/abstract/2\">",
"      Alcalay J, Alkalay R. Controversies in perioperative management of blood thinners in dermatologic surgery: continue or discontinue? Dermatol Surg 2004; 30:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31543/abstract/3\">",
"      Karimzadegan-Nia M, Mir-Amin-Mohammadi A, Bouzari N, Firooz A. Comparison of direct smear, culture and histology for the diagnosis of onychomycosis. Australas J Dermatol 2007; 48:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31543/abstract/4\">",
"      Lilly KK, Koshnick RL, Grill JP, et al. Cost-effectiveness of diagnostic tests for toenail onychomycosis: a repeated-measure, single-blinded, cross-sectional evaluation of 7 diagnostic tests. J Am Acad Dermatol 2006; 55:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31543/abstract/5\">",
"      Weinberg JM, Koestenblatt EK, Tutrone WD, et al. Comparison of diagnostic methods in the evaluation of onychomycosis. J Am Acad Dermatol 2003; 49:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31543/abstract/6\">",
"      Kuflik EG. Cryosurgery updated. J Am Acad Dermatol 1994; 31:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31543/abstract/7\">",
"      Thissen MR, Neumann MH, Schouten LJ. A systematic review of treatment modalities for primary basal cell carcinomas. Arch Dermatol 1999; 135:1177.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5562 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-77B11294E8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_51_31543=[""].join("\n");
var outline_f30_51_31543=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4330984\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4044225\">",
"      WOOD'S LAMP EXAMINATION (BLACK LIGHT)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4044232\">",
"      Equipment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4044239\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4044329\">",
"      DERMOSCOPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4044416\">",
"      POTASSIUM HYDROXIDE (KOH) PREP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4044423\">",
"      Equipment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4044430\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      FUNGAL CULTURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Equipment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TZANCK SMEAR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Equipment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4044140\">",
"      TOPICAL ANESTHESIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4044147\">",
"      Ice or ethyl chloride",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4044154\">",
"      Topical lidocaine preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4044161\">",
"      0.9 percent normal saline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4044168\">",
"      Combinations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SKIN BIOPSY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4044550\">",
"      INTRALESIONAL INJECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      CRYOSURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Equipment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      CURETTAGE AND ELECTRODESICCATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Equipment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      CYST EXCISION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Equipment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      WOUND CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4330984\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/5562\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5562|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/2/4132\" title=\"picture 1A\">",
"      Dermatophyte KOH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/37/28242\" title=\"picture 1B\">",
"      Hyphae candida albicans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/33/30228\" title=\"picture 1C\">",
"      Tinea versicolor KOH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/12/41167\" title=\"picture 2\">",
"      Candida albicans culture plate",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40265?source=related_link\">",
"      Clinical manifestations and diagnosis of herpes simplex virus type 1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/11/13497?source=related_link\">",
"      Dermoscopic evaluation of skin lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33689?source=related_link\">",
"      Infiltration of local anesthetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/45/40660?source=related_link\">",
"      Intralesional injection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/50/35626?source=related_link\">",
"      Management of anticoagulation before and after elective surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/34/553?source=related_link\">",
"      Overview of benign lesions of the skin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/57/38807?source=related_link\">",
"      Overview of dermoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40264?source=related_link\">",
"      Skin biopsy techniques",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_51_31544="Mouse genetics: Breeding strategies and genetic engineering";
var content_f30_51_31544=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mouse genetics: Breeding strategies and genetic engineering",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/51/31544/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/51/31544/contributors\">",
"     Robert D Blank, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/51/31544/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/51/31544/contributors\">",
"     Benjamin A Raby, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/51/31544/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/51/31544/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/51/31544/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory mice are among the most widely used model systems in biomedical research.",
"   </p>",
"   <p>",
"    The breeding strategies and genetics of laboratory mice are introduced in this topic review. Detailed information regarding specific mouse strains and breeding constructs are available online at the Jackson Laboratory web site (",
"    <a class=\"external\" href=\"file://www.jax.org/\">",
"     www.jax.org",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INBRED MICE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strains of inbred mice are model organisms for genetic studies, with hundreds of inbred strains in existence. For the purposes of genetic investigations, the key properties of inbred mice are that they are essentially isogenic and homozygous. Isogenicity means that sex-matched individuals have the same genotype across the entire genome. Homozygosity means that both chromosomes carry the same allele of each locus.",
"   </p>",
"   <p>",
"    Concepts of inbreeding were introduced in a classic paper from 1931 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31544/abstract/1\">",
"     1",
"    </a>",
"    ]. A brief summary of the principles and standards of inbreeding includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The generally accepted criterion for a strain to be considered inbred is 20 generations of brother-sister mating, or alternative breeding schemes that lead to an equivalent reduction of heterozygosity. Although historically 20 generations of full-sib inbreeding were considered to be sufficient to fix the genotype of an inbred line, with an expected residual heterozygosity of less than 0.1 percent, it has now been shown that considerably more inbreeding is needed to fix the genome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/51/31544/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Many inbred strains are complex hybrids whose ancestry includes mice that would not have interbred in the wild. For this reason, the amount of genetic variability among laboratory mice is extremely large.",
"     </li>",
"     <li>",
"      Nomenclature standards have been developed regarding mouse strain and substrain designations. Substrains are stocks separated after inbred status has been achieved. In general, the strain name is given first, followed by a slash, and then the substrain designation and when applicable, by information regarding mutations or transgenes.",
"     </li>",
"     <li>",
"      Not all mice having official names are inbred, and some nominal \"substrain\" differences are in fact strain differences for which nomenclature exceptions have been made because of historical precedent (eg,",
"      <span class=\"nowrap\">",
"       C57BL/6",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       C57BL/10).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Strictly speaking, new mutations and residual heterozygosity may contribute to non-isogenicity even within an inbred strain, but in most settings this is not an important issue. However, the potential accumulation of differences over time underlies the need to identify both strain and substrain when identifying mice. For these reasons, a single genotype suffices to describe all sex-matched individuals of a single substrain.",
"   </p>",
"   <p>",
"    F1 animals, the first generation obtained from a cross between parents of different inbred strains, are isogenic but not homozygous. They have all inherited the same alleles from their inbred parents, but one chromosome of each pair is derived from the maternal strain and the other is derived from the paternal strain. The mitochondrial genome is derived from the maternal strain, and it is therefore important to specify the maternal and paternal strains. By convention, in notating crosses, the dam (female) is listed first and the sire (male) second.",
"   </p>",
"   <p>",
"    These features allow investigation of both linkage and association in experimental mouse crosses:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Linkage is the determination of the chromosomal location of a gene influencing a trait",
"     </li>",
"     <li>",
"      Association is the relationship between a specific allele and the trait",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In analyzing the genetic basis of disease, we seek knowledge of both of these complementary properties. A standard mouse intercross is a biallelic study, in which only two alleles (one derived from each parent) are segregating. In contrast, natural human populations are multiallelic.",
"   </p>",
"   <p>",
"    It is not necessary for an experimental mouse intercross to be limited to two progenitor strains, however. A greater range of alleles can be achieved by increasing the number of progenitors to four or more [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31544/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, the intercross can be continued beyond F2, increasing the precision with which genes can be mapped [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31544/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Finally, the dense linkage map of the mouse, together with extensive genotypic data of the inbred mouse strains, makes most mouse crosses fully informative. In contrast, human crosses depend on finding markers in which different alleles can be identified within the study population.",
"   </p>",
"   <p>",
"    The biallelic nature of many mouse crosses, the ability to control breeding by designating matings, and the known genotypic data of inbred mouse strains greatly simplifies interpretation of the genetic results of experimental breeding relative to the analysis of a human pedigree study. However, this relative simplicity also poses important limitations for the use of inbred mice as models for human genetics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SPECIAL BREEDING SCHEMES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Recombinant inbred strains",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recombinant inbred (RI) strains are inbred strains established from brother-sister pairs of F2 intercross mice obtained from inbred progenitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31544/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The breeding scheme is illustrated in a figure (",
"    <a class=\"graphic graphic_figure graphicRef62083 \" href=\"mobipreview.htm?19/2/19503\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31544/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. They are isogenic and homozygous, like other inbred strains, and at any given locus they carry either of the progenitor strain alleles.",
"   </p>",
"   <p>",
"    RI strains are constructed as a series from a single initial intercross. Subsequently, because of crossing over and segregation, the effectively random locations of crossovers during the inbreeding process results in each strain in the series having a different complement of alleles derived from each of the progenitors. Any individual strain in a two-progenitor series is expected to have half of its genome derived from each progenitor strain. More than twenty generations of brother-sister inbreeding are needed for establishment of RI strains. RI strains are powerful mapping tools for monogenic traits and are also useful in mapping polygenic traits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31544/abstract/2,9,10\">",
"     2,9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Congenic strains",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenic strains are those in which a specific genetic locus is transferred onto a different recipient strain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31544/abstract/6,11\">",
"     6,11",
"    </a>",
"    ]. The breeding scheme is illustrated in a figure (",
"    <a class=\"graphic graphic_figure graphicRef63654 \" href=\"mobipreview.htm?12/31/12798\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31544/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Since linkage frequently carries neighboring genes along with the target locus into the recipient, this type of strain is generated to evaluate the effect of a gene in isolation from the effect of strain background.",
"   </p>",
"   <p>",
"    Because the donor segment includes more than just a single gene, only relative isolation of the target gene is achieved. Traditionally, 10 generations of backcrossing to the recipient strain, with selection at each generation for the presence of the desired donor locus, followed by brother-sister mating thereafter, has been the standard of inbreeding for congenic strains. This standard is theoretically equivalent to 20 generations of brother-sister inbreeding.",
"   </p>",
"   <p>",
"    Many investigators use marker-assisted selection to accelerate the pace at which donor alleles unlinked to the target locus are lost. This approach relies on the fact that while the expected loss of donor alleles is 50 percent at each generation, the actual loss of donor alleles in an individual mouse may be more or less than theoretical expectation. By selecting as breeders those individuals with the least number of donor alleles, the number of generations needed to achieve 99.9 percent homozygosity at unlinked loci can be reduced by three generations, corresponding to a time saving of nearly one year. This approach has therefore been called \"speed congenic\" breeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31544/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Congenic strains first became widely used in immunologic experiments, in which the major histocompatibility complex was transferred between inbred strains. It has subsequently become standard practice to construct congenic strains for quantitative trait loci identified in intercrosses, utilizing negative selection for unlinked donor alleles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Recombinant congenic strains",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recombinant congenic (RC) strains combine elements of breeding from both RI and congenic breeding schemes. Initially, several generations of backcrossing (usually two) are performed, followed by subsequent brother-sister inbreeding (",
"    <a class=\"graphic graphic_algorithm graphicRef75129 \" href=\"mobipreview.htm?3/20/3393\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31544/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As in congenic strains, the initial backcrosses reduce the contribution of the donor strain to the final genotype of individual RC strains. As in RI strains and in contrast to congenic strains, there is generally no selection for which specific donor chromosome segments are included in RC strains. Conceptually, one might consider RC strains to be \"unbalanced\" RI strains; while RI strains derive half of their alleles from each progenitor, 2nd backcross (N3) RC strain derive one-eighth of their alleles from the donor progenitor and the remainder from the recipient progenitor. RC strains are used in mapping polygenic traits and studying epistasis, or interactions between genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31544/abstract/10,18-20\">",
"     10,18-20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Chromosome substitution strains",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chromosome substitution (CS) strains are intended to facilitate mapping of quantitative traits, by moving chromosomes from a donor strain to a recipient strain. As for RC strains, the contributions of the donor chromosomes are unequal. Unlike the situation for RC strains, the donor contribution is theoretically restricted to a single chromosome, obviating the need for gross mapping of the relevant loci [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31544/abstract/21\">",
"     21",
"    </a>",
"    ]. Constructing CS strains relies on the same principles used in generating congenic strains, except that selection for markers spanning the donor chromosome are used simultaneously, rather than a single marker as in the case of congenic strains. Few CS strains have been bred thus far, so their use has been limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31544/abstract/22-25\">",
"     22-25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     The collaborative cross",
"    </span>",
"    &nbsp;&mdash;&nbsp;An ongoing effort has been to produce a mouse resource for genetic mapping that overcomes the limitations of inbreeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31544/abstract/26\">",
"     26",
"    </a>",
"    ]. The objective is to generate a series of 1000 eight-progenitor recombinant inbred strains. The progenitors are chosen to include more than 80 percent of the known interstrain diversity among present inbred mouse strains. F1 animals produced from such strains are isogenic, outbred, and possess haplotype blocks whose length approaches those of natural outbred populations.",
"   </p>",
"   <p>",
"    Combinational mating among these inbred strains will allow 4 to the 1000th power outbred genotypes to be produced in multiple animals, where \"4\" represents two sexes and two cross directions. The number of potential genotypes would therefore be orders of magnitude larger than is necessary for application of the methods of genomewide association studies (GWAS). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/38/3689?source=see_link\">",
"     \"Genetic association studies: Principles and applications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The short haplotype blocks will allow localization of functionally important genetic variation to short genomic segments. Thus, the advantages of isogeneity will be maintained, including the need to perform genotyping only once, and the ability to estimate phenotype from the pooling of multiple animals. The collaborative cross mice, however, will overcome limitations of the genetic resolving power of currently available mouse strains.",
"   </p>",
"   <p>",
"    As of early 2010, more than 1000 incipient RI strains are in production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31544/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. The first group of strains is approaching the N23 generation of inbreeding. Not every strain survives the breeding program, with many experiencing reproductive failure between the N4 and N8 generations. The RI lines are being produced and maintained at several sites worldwide. Subsequent work has confirmed that the theoretical potential of the collaborative cross is in fact being realized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31544/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     OUTBRED MICE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some commonly used mice are outbred, ie, bred specifically to maintain heterozygosity over much of the genome. Examples include Swiss and CD-1 mice, which are commercially available from major vendors. Such mice are generally healthy, vigorous, and long-lived. In general, such mice are preferred for investigations in which genetic constitution is not an issue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     LARGE SCALE MUTAGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large scale mutagenesis projects represent an alternative strategy for finding genes that affect specific phenotypes. Typically, single base mutations are produced. Mutagenesis projects depend critically on the ability to recognize abnormal phenotypes reliably and easily, as many mice must be examined to find the desired mutants. Consequently, the mutagenesis strategy relies on generating viable mutants at high frequency, using robust methods to screen mutants, and applying efficient methods for mapping the mutated genes.",
"   </p>",
"   <p>",
"    Notable successes have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31544/abstract/31\">",
"     31",
"    </a>",
"    ]. As an example, the Golgi protein GMAP-210, encoded by Trip11, provides a specific highlight of a mouse mutagenesis screen identifying a gene responsible for a human disease. The mutant mouse gene caused shortened limbs, failure of osteogenesis at multiple sites, and apoptosis of growth plate chondrocytes, culminating in lethality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31544/abstract/32\">",
"     32",
"    </a>",
"    ]. These investigators recognized that the mutant mice resemble humans with achondrogenesis type 1A, and found mutations in the human Trip11 gene in 10 patients with the disorder who were not related to each other.",
"   </p>",
"   <p>",
"    Various project websites with information regarding other studies include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"external\" href=\"file://www.har.mrc.ac.uk/\">",
"       www.har.mrc.ac.uk/",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://nmf.jax.org/\">",
"       file://nmf.jax.org/",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.genome.northwestern.edu/neuro/\">",
"       www.genome.northwestern.edu/neuro/",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.cmhd.ca/enu_mutagenesis/index.html\">",
"       www.cmhd.ca/enu_mutagenesis/index.html",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.mouse-genome.bcm.tmc.edu/enu/mutagenesisproj.asp\">",
"       www.mouse-genome.bcm.tmc.edu/enu/mutagenesisproj.asp",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.tnmouse.org/neuromutagenesis/\">",
"       www.tnmouse.org/neuromutagenesis/",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     GENETICALLY ENGINEERED MICE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Technical underpinnings",
"    </span>",
"    &nbsp;&mdash;&nbsp;To understand the various genetically engineered mouse systems, it is necessary to appreciate the technologies used to construct them. Fundamental to all such experiments is the ability to carry out molecular cloning and molecular biological manipulations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31544/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. Specific methods used to introduce engineered DNA into mice are available in standard laboratory references [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31544/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The fundamental technology at the core of most genetically engineered mice is the ability to introduce foreign DNA into pluripotent recipient cells. In practice, this is accomplished either by direct microinjection of DNA into a fertilized egg (",
"    <a class=\"graphic graphic_picture graphicRef77166 \" href=\"mobipreview.htm?34/39/35454\">",
"     picture 1",
"    </a>",
"    ), or by transfection into mouse embryonic stem (ES) cells.",
"   </p>",
"   <p>",
"    ES cells are pluripotent cells that can give rise to all tissues, including the germline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31544/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. ES cells can be grown in culture and subjected to transfection and selection in the same manner as other cultured cells. Typically, targeted transfection relies upon a combination of selection for resistance to selective agents, Southern blotting, and polymerase chain reaction (PCR) to verify that exogenous DNA has been incorporated into the correct target site. ES cells shown to harbor the desired construct are then injected into mouse blastocysts, to yield chimeric embryos. The blastocysts can then be implanted into foster mothers, which then carry the pregnancy to term.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Transgenic mice",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transgenic mice are those into which foreign DNA has been incorporated into the genome. According to this broad definition, all types of genetically engineered mice are transgenic. In a more narrow sense, transgenic mice have an \"extra\" gene introduced to accomplish any of several experimental objectives:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To correct pathology caused by mutation, thus proving that the transgene complements the preexisting mutation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/51/31544/abstract/41\">",
"       41",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      To introduce a reporter gene under specified genetic control to identify tissues and times at which the included control is active [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/51/31544/abstract/42\">",
"       42",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      To introduce an abnormal gene, thus creating a disease model [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/51/31544/abstract/43\">",
"       43",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Simple transgenics, in which no attempt is made to target the construct to a specific site in the genome, can be generated by microinjecting DNA directly into one of the pronuclei of fertilized eggs in vitro. Surviving blastocysts are implanted into foster mothers and pups analyzed for presence of the transgene. Early work was typically performed using outbred eggs, but now much microinjection work is performed using eggs obtained from",
"    <span class=\"nowrap\">",
"     FVB/N",
"    </span>",
"    mice, which have large pronuclei and breed well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31544/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Knockout mice",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to simple transgenic animals, knockout mice depend upon successful gene targeting to disrupt the target gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31544/abstract/45\">",
"     45",
"    </a>",
"    ]. This is achieved by using genetic selection to enrich transfected ES cells for successful targeting. Targeting vectors for mammalian cells use a combination of positive selection (incorporation and retention of a selected marker) and negative selection (loss of a second selected marker) (",
"    <a class=\"graphic graphic_figure graphicRef79203 \" href=\"mobipreview.htm?17/2/17442\">",
"     figure 3",
"    </a>",
"    ). Technical aspects of constructing the necessary targeting vectors have advanced in recent years, and feature bacterial artificial chromosome clones prepared from",
"    <span class=\"nowrap\">",
"     129/Sv",
"    </span>",
"    mice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31544/abstract/46\">",
"     46",
"    </a>",
"    ] and a \"recombineering\" host-vector system in which some steps are accomplished in vivo in bacteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31544/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The motivation for doing this is to study the consequences of loss of function of the targeted gene directly in vivo. In contrast to experiments using cultured cells, the knockout allows the consequences of target gene disruption to be evaluated in the context of whole-organism physiology. In this setting, it is possible to study physiological adaptation to the knockout and discover effects in tissues in which pathology might not have been suspected a priori. Comparison and contrast among knockout phenotypes for related target genes help to identify both the unique and redundant functions of their products.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Knock-in mice",
"    </span>",
"    &nbsp;&mdash;&nbsp;Knock-in mice are theoretically similar to knockout mice, with the important difference that an altered rather than a null version of the target gene is substituted for the naturally occurring allele. Knock-in technology allows examination of the effects of different mutations on the same gene. This is particularly informative if the mutations thought to cause human disease result in gain of function rather than loss of function (eg, oncogenes) or if the goal is to investigate a mutant in a single tissue (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Conditional systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some gene disruptions are lethal or lethal too early in development to allow fruitful investigation of their consequences. A variety of methods have been developed to overcome this class of problems. These are briefly described here.",
"   </p>",
"   <p>",
"    Modulating transgene expression can be achieved by placing the transgene under the transcriptional control of an inducible promoter. The bacterial",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    resistance operon provides such a reagent system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31544/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. The investigator can then regulate transgene expression by titrating administration of tetracycline to the transgenic animals.",
"   </p>",
"   <p>",
"    A strategy by which knockout expression can be restricted is generation of tissue-specific knockouts. This approach exploits the ability of bacteriophage P1 Cre recombinase to mediate site-specific recombination at specific short sequence elements called loxP sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31544/abstract/51\">",
"     51",
"    </a>",
"    ]. Two engineered mice must be produced to carry out such an experiment. One construct introduces the loxP sites into the target gene, flanking sufficient DNA so that its deletion will achieve the desired loss of target gene activity. The second construct, which can be a simple transgene, introduces a functional gene for Cre recombinase driven by a tissue-specific promoter. Mice homozygous for the target gene construct are then mated to mice harboring the tissue-specific Cre construct. Offspring receiving the construct (expected to be 50 percent of the progeny) will express Cre recombinase in a tissue-specific manner, leading to excision of the portion of the target gene flanked by the loxP sites, thus knocking out the gene in that tissue exclusively (",
"    <a class=\"graphic graphic_figure graphicRef51486 \" href=\"mobipreview.htm?39/17/40213\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31544/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Many investigators test the biological function of the Cre transgene by mating it to any of several available \"reporter\" mice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31544/abstract/54-60\">",
"     54-60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Collaborative projects in North America and in Europe have developed conditional knockout alleles for thousands of genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31544/abstract/61-64\">",
"     61-64",
"    </a>",
"    ]. In addition to Cre reporter mice, there are also reporter mice that can identify the anatomic sites at which specific biologic pathways are active. As an example, the TOPGAL mouse expressed beta-galactosidase at sites of canonical Wnt signaling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31544/abstract/65\">",
"     65",
"    </a>",
"    ], allowing investigators to identify the tissues in which the pathway is active.",
"   </p>",
"   <p>",
"    The extraembryonic tissues are important in early developmental steps including gastrulation. One group developed a method by which early embryos can be tetraploidized, and chimeric embryos produced from tetraploidized embryos and cultured ES cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31544/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. Under these conditions, the tetraploid cells give rise exclusively to extraembryonic tissue, while the diploid ES cells produce all of the embryo proper. This approach allows investigators to overcome some early developmental defects, thus allowing later functions of the disrupted gene to be studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31544/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Limitations and caveats",
"    </span>",
"    &nbsp;&mdash;&nbsp;Characteristics of inbred strains are highly variable, so knowing the background in which a genetic construct has been studied is essential to interpreting its biology. For technical reasons, many genetically engineered mice have been generated on one of the 129 strains, which recently have been found to be more diverse than previously believed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31544/abstract/70-72\">",
"     70-72",
"    </a>",
"    ]. Investigators routinely breed founder animals to a recipient strain, most often",
"    <span class=\"nowrap\">",
"     C57BL/6.",
"    </span>",
"    Consequently, the constructs are often studied on a poorly-defined \"mixed 129 X",
"    <span class=\"nowrap\">",
"     C57BL/6",
"    </span>",
"    background,\" without further information regarding the relative contributions of the progenitor genomes, number of generations of subsequent inbreeding, or often even the correct strain information regarding the progenitors. While unfortunate, this is the status of most of the extant literature. Efforts to improve reporting of strain background in the future are underway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31544/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For mice in which the construct has not been targeted to a specific locus, incorporation of the transgene may result in insertional mutagenesis, with the resulting phenotype arising not from the transgene, but from disruption of the gene into which the transgene was placed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31544/abstract/74\">",
"     74",
"    </a>",
"    ]. The transgene's expression may also be variable according to the properties of the insertion site [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31544/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A third complication is the usual result of multiple copies of the transgene being inserted into the genome, with consequent differences in transgene expression level. These limitations can be addressed by targeting transgenes to specific sites. One site that allows insertion of a single copy of the transgene while allowing transcription to be mediated by sequences included in the targeting vector is the HPRT locus, encoding the salvage purine utilization enzyme",
"    <span class=\"nowrap\">",
"     hypoxanthine/guanine",
"    </span>",
"    phosphoribosyl transferase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31544/abstract/76,77\">",
"     76,77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major limitation of knockouts is that the allele generated is, by design, null. Therefore, while they are useful for establishing the role of the target gene in a pathway, it is not necessarily the case that mutations in the target gene account for human diseases or population variation in downstream phenotypes mediated by it. Knock-in strategies can address this by allowing study of a series of mutant alleles. By virtue of being targeted to the homologous locus, the issue of unintentional insertional mutation does not arise with knockout mice. The limitations related to strain background are significant, particularly because 129 related strains have been the source of most ES cell lines. More recent success in generating successful ES cells from other strains promises to mitigate this problem in the future [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31544/abstract/78,79\">",
"     78,79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The practical response to these limitations is that when transgenic mice are generated, investigators routinely study animals derived from several different founders. The minimal characterization will generally include estimation of copy number, transgene mRNA level, and transgene protein level. More detailed analysis is then conducted on one or a small number of the transgenic lines. Careful investigators will also report the breeding history between founder and the analyzed animals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laboratory mice are among the most widely used model systems in biomedical research. The key properties of inbred mice relative to genetics studies are that they are isogenic and homozygous. F1 animals, the first generation obtained from a cross between parents of different inbred strains, are isogenic but not homozygous. Isogenicity allows study of multiple animals sharing a single genotype, thus allowing better estimation of the phenotype being studied. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Inbred mice'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recombinant inbred strains, the result of a series of brother-sister matings from an initial intercross, allow gene mapping (",
"      <a class=\"graphic graphic_figure graphicRef62083 \" href=\"mobipreview.htm?19/2/19503\">",
"       figure 1",
"      </a>",
"      ). Congenic strains, in which a specific genetic locus is transferred onto a different recipient strain (",
"      <a class=\"graphic graphic_figure graphicRef63654 \" href=\"mobipreview.htm?12/31/12798\">",
"       figure 2",
"      </a>",
"      ), allow evaluation of a gene in isolation from the effect of strain background. Chromosome substitution (CS) strains facilitate mapping of quantitative traits by moving chromosomes from a donor strain to a recipient strain. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Special breeding schemes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The collaborative cross preserves the key advantage of isogenicity, while overcoming many of the limitations of inbred mice. This model better approximates the human genetic structure by being outbred and having a preponderance of short haplotype blocks, making this a powerful tool for relating phenotypes to specific DNA variants. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'The collaborative cross'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The ability to introduce foreign DNA into pluripotent recipient cells is at the core of most genetically engineered mice. Transgenic mice are those into which foreign DNA has been incorporated into the genome. Knockout mice depend upon successful gene transfer targeted to disrupt a specific gene to study the consequences of loss of function of the targeted gene directly in vivo. Knock-in technology allows examination of the effects of different mutations on the same gene. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Genetically engineered mice'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/1\">",
"      Haldane JB, Waddington CH. Inbreeding and Linkage. Genetics 1931; 16:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/2\">",
"      Broman KW. The genomes of recombinant inbred lines. Genetics 2005; 169:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/3\">",
"      RODERICK TH. Selection for radiation resistance in mice. Genetics 1963; 48:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/4\">",
"      Darvasi A, Soller M. Advanced intercross lines, an experimental population for fine genetic mapping. Genetics 1995; 141:1199.",
"     </a>",
"    </li>",
"    <li>",
"     Taylor BA. Recombinant inbred strains: Use in gene mapping. In: Origins of Inbred Mice, Morse HC (Ed), Academic Press, New York 1978. p.423.",
"    </li>",
"    <li>",
"     Bailey DW. Recombinant inbred strains and bilineal congenic strains. In: The Mouse in Biomedical Research, Foster HL, Small JD, Fox JG (Eds), Academic Press, New York 1981. p.223.",
"    </li>",
"    <li>",
"     Silver LM. Mouse Genetics, Oxford University Press, New York 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/8\">",
"      Blake JA, Eppig JT, Richardson JE, et al. The Mouse Genome Database (MGD): integration nexus for the laboratory mouse. Nucleic Acids Res 2001; 29:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/9\">",
"      Plomin R, McClearn GE, Gora-Maslak G, Neiderhiser JM. Use of recombinant inbred strains to detect quantitative trait loci associated with behavior. Behav Genet 1991; 21:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/10\">",
"      Darvasi A. Experimental strategies for the genetic dissection of complex traits in animal models. Nat Genet 1998; 18:19.",
"     </a>",
"    </li>",
"    <li>",
"     Flaherty L. Congenic Strains. In: The Mouse in Biomedical Research: History, Genetics, and Wild Mice, Small JD, Fox JG (Eds), Academic Press, New York 1981. p.215.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/12\">",
"      Visscher PM. Speed congenics: accelerated genome recovery using genetic markers. Genet Res 1999; 74:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/13\">",
"      Wakeland E, Morel L, Achey K, et al. Speed congenics: a classic technique in the fast lane (relatively speaking). Immunol Today 1997; 18:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/14\">",
"      Markel P, Shu P, Ebeling C, et al. Theoretical and empirical issues for marker-assisted breeding of congenic mouse strains. Nat Genet 1997; 17:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/15\">",
"      D&eacute;mant P, Hart AA. Recombinant congenic strains--a new tool for analyzing genetic traits determined by more than one gene. Immunogenetics 1986; 24:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/16\">",
"      van Zutphen LF, Den Bieman M, Lankhorst A, Demant P. Segregation of genes from donor strain during the production of recombinant congenic strains. Lab Anim 1991; 25:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/17\">",
"      Moen CJ, van der Valk MA, Snoek M, et al. The recombinant congenic strains--a novel genetic tool applied to the study of colon tumor development in the mouse. Mamm Genome 1991; 1:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/18\">",
"      Fijneman RJ, de Vries SS, Jansen RC, Demant P. Complex interactions of new quantitative trait loci, Sluc1, Sluc2, Sluc3, and Sluc4, that influence the susceptibility to lung cancer in the mouse. Nat Genet 1996; 14:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/19\">",
"      van Wezel T, Stassen AP, Moen CJ, et al. Gene interaction and single gene effects in colon tumour susceptibility in mice. Nat Genet 1996; 14:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/20\">",
"      Frankel WN, Schork NJ. Who's afraid of epistasis? Nat Genet 1996; 14:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/21\">",
"      Nadeau JH, Singer JB, Matin A, Lander ES. Analysing complex genetic traits with chromosome substitution strains. Nat Genet 2000; 24:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/22\">",
"      Hudgins CC, Steinberg RT, Klinman DM, et al. Studies of consomic mice bearing the Y chromosome of the BXSB mouse. J Immunol 1985; 134:3849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/23\">",
"      Eales BA, Nahas M, Biddle FG. Directional dominance and a developmental model for the expression of the Tda testis-determining autosomal trait of the mouse. Genome 1996; 39:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/24\">",
"      Matin A, Collin GB, Asada Y, et al. Susceptibility to testicular germ-cell tumours in a 129.MOLF-Chr 19 chromosome substitution strain. Nat Genet 1999; 23:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/25\">",
"      Ulbrich M, Schmidt VC, Ronsiek M, et al. Genetic modifiers that aggravate the neurological phenotype of the wobbler mouse. Neuroreport 2002; 13:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/26\">",
"      Churchill GA, Airey DC, Allayee H, et al. The Collaborative Cross, a community resource for the genetic analysis of complex traits. Nat Genet 2004; 36:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/27\">",
"      Morahan G, Balmer L, Monley D. Establishment of \"The Gene Mine\": a resource for rapid identification of complex trait genes. Mamm Genome 2008; 19:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/28\">",
"      Chesler EJ, Miller DR, Branstetter LR, et al. The Collaborative Cross at Oak Ridge National Laboratory: developing a powerful resource for systems genetics. Mamm Genome 2008; 19:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/29\">",
"      Iraqi FA, Churchill G, Mott R. The Collaborative Cross, developing a resource for mammalian systems genetics: a status report of the Wellcome Trust cohort. Mamm Genome 2008; 19:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/30\">",
"      Aylor DL, Valdar W, Foulds-Mathes W, et al. Genetic analysis of complex traits in the emerging Collaborative Cross. Genome Res 2011; 21:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/31\">",
"      Acevedo-Arozena A, Wells S, Potter P, et al. ENU mutagenesis, a way forward to understand gene function. Annu Rev Genomics Hum Genet 2008; 9:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/32\">",
"      Smits P, Bolton AD, Funari V, et al. Lethal skeletal dysplasia in mice and humans lacking the golgin GMAP-210. N Engl J Med 2010; 362:206.",
"     </a>",
"    </li>",
"    <li>",
"     Ausubel FM, Brent R, Kingston RE, et al. Current Protocols in Molecular Biology. In: Current Protocols, Janssen (Ed), Greene Publishing Associates, Inc. and John Wiley &amp; Sons, Inc., New York 1996.",
"    </li>",
"    <li>",
"     Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual, Cold Spring Laboratory Press, Cold Spring Harbor, NY 1989.",
"    </li>",
"    <li>",
"     Gene Targeting: A Practical Approach, 2nd ed, Joyner AL (Ed), Oxford University Press, New York 2000.",
"    </li>",
"    <li>",
"     Manipulating the Mouse Embryo: Laboratory Manual, Hogan B, Beddington R, Costantini F, Lacy E (Eds), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 1994.",
"    </li>",
"    <li>",
"     Mouse Genetics and Transgenics: A Practical Approach, Jackson IJ, Abbott CM (Eds), Oxford University Press, New York 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/38\">",
"      Bradley A, Evans M, Kaufman MH, Robertson E. Formation of germ-line chimaeras from embryo-derived teratocarcinoma cell lines. Nature 1984; 309:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/39\">",
"      Robertson E, Bradley A, Kuehn M, Evans M. Germ-line transmission of genes introduced into cultured pluripotential cells by retroviral vector. Nature 1986; 323:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/40\">",
"      Martin GR. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc Natl Acad Sci U S A 1981; 78:7634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/41\">",
"      Hardin JD, Boast S, Mendelsohn M, et al. Transgenes encoding both type I and type IV c-abl proteins rescue the lethality of c-abl mutant mice. Oncogene 1996; 12:2669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/42\">",
"      Kalajzic I, Kalajzic Z, Kaliterna M, et al. Use of type I collagen green fluorescent protein transgenes to identify subpopulations of cells at different stages of the osteoblast lineage. J Bone Miner Res 2002; 17:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/43\">",
"      Khillan JS, Olsen AS, Kontusaari S, et al. Transgenic mice that express a mini-gene version of the human gene for type I procollagen (COL1A1) develop a phenotype resembling a lethal form of osteogenesis imperfecta. J Biol Chem 1991; 266:23373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/44\">",
"      Taketo M, Schroeder AC, Mobraaten LE, et al. FVB/N: an inbred mouse strain preferable for transgenic analyses. Proc Natl Acad Sci U S A 1991; 88:2065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/45\">",
"      Mansour SL, Thomas KR, Capecchi MR. Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes. Nature 1988; 336:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/46\">",
"      Adams DJ, Quail MA, Cox T, et al. A genome-wide, end-sequenced 129Sv BAC library resource for targeting vector construction. Genomics 2005; 86:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/47\">",
"      Liu P, Jenkins NA, Copeland NG. A highly efficient recombineering-based method for generating conditional knockout mutations. Genome Res 2003; 13:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/48\">",
"      Fedorov LM, Tyrsin OY, Krenn V, et al. Tet-system for the regulation of gene expression during embryonic development. Transgenic Res 2001; 10:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/49\">",
"      Bohl D, Heard JM. Modulation of erythropoietin delivery from engineered muscles in mice. Hum Gene Ther 1997; 8:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/50\">",
"      Paulus W, Baur I, Boyce FM, et al. Self-contained, tetracycline-regulated retroviral vector system for gene delivery to mammalian cells. J Virol 1996; 70:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/51\">",
"      Hoess RH, Ziese M, Sternberg N. P1 site-specific recombination: nucleotide sequence of the recombining sites. Proc Natl Acad Sci U S A 1982; 79:3398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/52\">",
"      Rajewsky K, Gu H, K&uuml;hn R, et al. Conditional gene targeting. J Clin Invest 1996; 98:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/53\">",
"      Rossant J, McMahon A. \"Cre\"-ating mouse mutants-a meeting review on conditional mouse genetics. Genes Dev 1999; 13:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/54\">",
"      Soriano P. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet 1999; 21:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/55\">",
"      Lobe CG, Koop KE, Kreppner W, et al. Z/AP, a double reporter for cre-mediated recombination. Dev Biol 1999; 208:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/56\">",
"      Mao X, Fujiwara Y, Orkin SH. Improved reporter strain for monitoring Cre recombinase-mediated DNA excisions in mice. Proc Natl Acad Sci U S A 1999; 96:5037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/57\">",
"      Kawamoto S, Niwa H, Tashiro F, et al. A novel reporter mouse strain that expresses enhanced green fluorescent protein upon Cre-mediated recombination. FEBS Lett 2000; 470:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/58\">",
"      Novak A, Guo C, Yang W, et al. Z/EG, a double reporter mouse line that expresses enhanced green fluorescent protein upon Cre-mediated excision. Genesis 2000; 28:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/59\">",
"      Mao X, Fujiwara Y, Chapdelaine A, et al. Activation of EGFP expression by Cre-mediated excision in a new ROSA26 reporter mouse strain. Blood 2001; 97:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/60\">",
"      Srinivas S, Watanabe T, Lin CS, et al. Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. BMC Dev Biol 2001; 1:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/61\">",
"      Schn&uuml;tgen F, De-Zolt S, Van Sloun P, et al. Genomewide production of multipurpose alleles for the functional analysis of the mouse genome. Proc Natl Acad Sci U S A 2005; 102:7221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/62\">",
"      Schn&uuml;tgen F. Generation of multipurpose alleles for the functional analysis of the mouse genome. Brief Funct Genomic Proteomic 2006; 5:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/63\">",
"      Floss T, Schn&uuml;tgen F. Conditional gene trapping using the FLEx system. Methods Mol Biol 2008; 435:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/64\">",
"      Friedel RH, Seisenberger C, Kaloff C, Wurst W. EUCOMM--the European conditional mouse mutagenesis program. Brief Funct Genomic Proteomic 2007; 6:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/65\">",
"      DasGupta R, Fuchs E. Multiple roles for activated LEF/TCF transcription complexes during hair follicle development and differentiation. Development 1999; 126:4557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/66\">",
"      Nagy A, Rossant J, Nagy R, et al. Derivation of completely cell culture-derived mice from early-passage embryonic stem cells. Proc Natl Acad Sci U S A 1993; 90:8424.",
"     </a>",
"    </li>",
"    <li>",
"     Nagy A, Rossant J. Production of completely ES cell-derived fetuses. In: Gene Targeting: A Practical Approach, Joyner AL (Ed), Oxford University Press, New York 1993. p.147.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/68\">",
"      Duncan SA, Nagy A, Chan W. Murine gastrulation requires HNF-4 regulated gene expression in the visceral endoderm: tetraploid rescue of Hnf-4(-/-) embryos. Development 1997; 124:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/69\">",
"      Li J, Ning G, Duncan SA. Mammalian hepatocyte differentiation requires the transcription factor HNF-4alpha. Genes Dev 2000; 14:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/70\">",
"      Threadgill DW, Yee D, Matin A, et al. Genealogy of the 129 inbred strains: 129/SvJ is a contaminated inbred strain. Mamm Genome 1997; 8:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/71\">",
"      Simpson EM, Linder CC, Sargent EE, et al. Genetic variation among 129 substrains and its importance for targeted mutagenesis in mice. Nat Genet 1997; 16:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/72\">",
"      Threadgill DW, Matin A, Yee D, et al. SSLPs to map genetic differences between the 129 inbred strains and closed-colony, random-bred CD-1 mice. Mamm Genome 1997; 8:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/73\">",
"      Festing MF, Simpson EM, Davisson MT, Mobraaten LE. Revised nomenclature for strain 129 mice. Mamm Genome 1999; 10:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/74\">",
"      Tutois S, Salaun J, Mattei MG, Gu&eacute;net JL. Tg (9 HSA-MYC), a homozygous lethal insertion in the mouse. Mamm Genome 1991; 1:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/75\">",
"      DeLoia JA, Solter D. A transgene insertional mutation at an imprinted locus in the mouse genome. Dev Suppl 1990; :73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/76\">",
"      Bronson SK, Plaehn EG, Kluckman KD, et al. Single-copy transgenic mice with chosen-site integration. Proc Natl Acad Sci U S A 1996; 93:9067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/77\">",
"      Misra RP, Bronson SK, Xiao Q, et al. Generation of single-copy transgenic mouse embryos directly from ES cells by tetraploid embryo complementation. BMC Biotechnol 2001; 1:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/78\">",
"      Kitani H, Takagi N, Atsumi T, et al. Isolation of a germline-transmissible embryonic stem (ES) cell line from C3H/He mice. Zoolog Sci 1996; 13:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31544/abstract/79\">",
"      Schuster-Gossler K, Lee AW, Lerner CP, et al. Use of coisogenic host blastocysts for efficient establishment of germline chimeras with C57BL/6J ES cell lines. Biotechniques 2001; 31:1022.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2894 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-DEDEA7E9BD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_51_31544=[""].join("\n");
var outline_f30_51_31544=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INBRED MICE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SPECIAL BREEDING SCHEMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Recombinant inbred strains",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Congenic strains",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Recombinant congenic strains",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Chromosome substitution strains",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      The collaborative cross",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      OUTBRED MICE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      LARGE SCALE MUTAGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      GENETICALLY ENGINEERED MICE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Technical underpinnings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Transgenic mice",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Knockout mice",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Knock-in mice",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Conditional systems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Limitations and caveats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/2894\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2894|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?3/20/3393\" title=\"algorithm 1\">",
"      Congenic breeding scheme",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2894|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/2/19503\" title=\"figure 1\">",
"      Construction RI strains",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/31/12798\" title=\"figure 2\">",
"      Creation congenic strain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/2/17442\" title=\"figure 3\">",
"      Generating DNA knockout mice",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/17/40213\" title=\"figure 4\">",
"      Tissue specific knockout const",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2894|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/39/35454\" title=\"picture 1\">",
"      Microinjection into fert egg",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/38/3689?source=related_link\">",
"      Genetic association studies: Principles and applications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_51_31545="Speech and swallowing rehabilitation of the patient with head and neck cancer";
var content_f30_51_31545=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Speech and swallowing rehabilitation of the patient with head and neck cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/51/31545/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/51/31545/contributors\">",
"     Jan S Lewin, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/51/31545/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/51/31545/contributors\">",
"     Bruce E Brockstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/51/31545/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/51/31545/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/51/31545/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with head and neck cancer face multiple, often severe psychological and functional problems associated with the diagnosis and treatment of their disease. Rehabilitation and restoration of speech and swallowing are critical to optimize quality of life following treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/24/3466?source=see_link\">",
"     \"Quality of life in head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Functional outcomes depend upon multiple factors, including the site of origin and stage of the cancer, treatment modality, extent of resection, type of reconstruction, and quality of rehabilitation. Anatomical preservation does not necessarily translate into preservation of organ function. Even treatments that permit organ preservation, surgical (eg, laser, robotic) or nonsurgical (eg, radiation therapy [RT] alone or in combination with chemotherapy [CRT]), frequently result in severe functional sequelae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/15/29946?source=see_link\">",
"     \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The critical components of speech and swallowing rehabilitation for the patient with head and neck cancer will be reviewed here. Alaryngeal speech restoration is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/54/16231?source=see_link\">",
"     \"Alaryngeal speech rehabilitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     THE INTERDISCIPLINARY TEAM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with head and neck cancer have a variety of speech and swallowing problems. Many factors contribute, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Loss of anatomic structure and continuity within the upper aerodigestive tract",
"     </li>",
"     <li>",
"      Altered salivary flow",
"     </li>",
"     <li>",
"      Altered dentition",
"     </li>",
"     <li>",
"      Mucositis",
"     </li>",
"     <li>",
"      Odynophagia and dysphagia",
"     </li>",
"     <li>",
"      Trismus",
"     </li>",
"     <li>",
"      Malnutrition and weight loss",
"     </li>",
"     <li>",
"      Treatment-related fibrosis",
"     </li>",
"     <li>",
"      Depression",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Successful treatment for head and neck cancer and posttreatment rehabilitation are facilitated by a strong interdisciplinary team approach to management. This point cannot be overemphasized. Pretreatment evaluation and planning should involve the entire patient care and rehabilitation team including at a minimum the surgeon, radiation oncologist, medical oncologist, dentist or maxillofacial prosthodontist, speech pathologist, nurse, dietitian, and social worker. Assistance from other specialists (eg, physical therapist, psychologist, pharmacist) may also be needed during the course of treatment.",
"   </p>",
"   <p>",
"    The attitude and preferences of the patient and the support of family and friends are essential components of treatment acceptance and compliance. Therefore, the patient and family (or significant other) must be included in the treatment planning process. Ideally, patients should meet with all members of the interdisciplinary team prior to the initiation of their cancer treatment. Recovery and rehabilitation are optimized when there is ongoing dialogue between all members of the interdisciplinary team and consistency in the information that is relayed to the patient.",
"   </p>",
"   <p>",
"    The need for speech and swallowing therapy is often unexpected by the patient and may be difficult to accept. Even though pretreatment difficulty in swallowing may be present in more than one-half of patients with head and neck cancer, these problems may not be self-perceived [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/2\">",
"     2",
"    </a>",
"    ]. Pretreatment counseling should provide realistic expectations for recovery and reinforce the patient's responsibility for active participation in an aggressive rehabilitation program. A baseline evaluation of speech and swallowing function should also be obtained for posttreatment comparison. A baseline examination of swallowing function also provides critical information for the prediction of posttreatment functioning. Patients who cannot swallow adequately before treatment are at greater risk for chronic swallowing impairment after treatment and are at greater risk for long-term feeding tube dependence. &nbsp;",
"   </p>",
"   <p>",
"    Routine pretreatment dental evaluation is critical for all patients regardless of the treatment modality. Rehabilitation of both speech and swallowing may be severely compromised by unplanned dental extractions, especially if appropriate consideration is not given to the stability of a possible intraoral prosthesis. In addition, the patient's dental status, dentate or edentulous, will affect speech and swallowing rehabilitation as well as final functional outcomes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/45/8919?source=see_link\">",
"     \"Management of acquired maxillary defects: Prosthetic rehabilitation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/1/22554?source=see_link&amp;anchor=H722455156#H722455156\">",
"     \"Management and prevention of complications of head and neck cancer during initial treatment\", section on 'Dental issues'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many patients are not routinely referred to a speech pathologist for pretreatment evaluation and counseling. Reasons include limited access to a knowledgeable speech pathologist, time constraints, and lack of awareness or misconception regarding the value of pretreatment speech pathology services. Some physicians believe such information may lead patients to refuse treatment. In fact, the opposite is true. Patients often report a sense of relief and an increased willingness to proceed with the treatment plan following counseling.",
"   </p>",
"   <p>",
"    Pretreatment counseling is designed to reduce fears and misconceptions of the patient and family while assuring them that rehabilitation will be available both during and after treatment to improve functional status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/3\">",
"     3",
"    </a>",
"    ]. It permits the patient and the family to assimilate information that is often overwhelming and frightening, and gives them an opportunity to ask the questions that concern them.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H524543925\">",
"    <span class=\"h1\">",
"     PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal speech and swallowing require precise coordination of a series of rapid, complex neuromuscular actions. Speech production is affected primarily by tumors that involve the tongue, other structures of the oral cavity, or the larynx. In contrast, swallowing can be affected by any cancer within the aerodigestive tract [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/4\">",
"     4",
"    </a>",
"    ]. Any alteration in oropharyngeal or laryngeal structures or their neural innervation that disrupt these neuromuscular patterns will have some effect on both speech and swallowing.",
"   </p>",
"   <p>",
"    Swallowing includes four discrete phases: the oral preparatory, oral, pharyngeal, and esophageal stages. These four biomechanical events occur in a predictable sequence, and each stage is based upon the movement patterns and timely occurrence of neurologic triggers from the previous stage. The oropharyngeal swallow consists of the first three stages only. These events begin at the lips and end at the upper esophageal sphincter. Aspects of voluntary and involuntary control characterize the various swallowing stages. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2037?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathogenesis and clinical manifestations of oropharyngeal dysphagia\", section on 'Physiology of swallowing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, normal swallowing requires intact anatomy, which can vary widely in size, shape, and symmetry in healthy individuals. These variations often affect swallowing but rarely compromise it. However, such variations may result in impaired swallowing or further decompensation in an otherwise debilitated patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     COMPLICATIONS AFTER RADIATION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy (RT) may be used as the primary treatment modality for early and some intermediate stage head and neck cancers, in combination with chemotherapy for organ-preserving approaches, as adjuvant therapy following surgical resection, or for palliation in patients with advanced disease. Regardless of the clinical intent, RT produces tissue changes that often result in long-term alterations in speech and swallowing. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/1/22554?source=see_link\">",
"     \"Management and prevention of complications of head and neck cancer during initial treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/42/30378?source=see_link\">",
"     \"Management of late complications of head and neck cancer and its treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, RT has a greater impact on swallowing than it does on speech [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/6,7\">",
"     6,7",
"    </a>",
"    ], and the addition of chemotherapy or use of altered fractionation schemes often exacerbate these effects, particularly during the acute recovery period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/4,8\">",
"     4,8",
"    </a>",
"    ]. The magnitude of the problem often depends upon the dose and duration of RT, the extent of the treatment field, and whether chemotherapy was used. Although the total dose of radiation is likely associated with the occurrence of late dysphagia, the threshold dose has not been clearly defined. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/57/23446?source=see_link\">",
"     \"Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/15/29946?source=see_link\">",
"     \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although late, severe dysphagia may be uncommon, when it occurs, the level of dysfunction is often intense and refractory to standard, non-surgical therapies. In a case series of 29 long-term (&ge;5 years) head and neck cancer survivors with late dysphagia treated with RT or chemoradiotherapy (CRT) from a single institution, 86 percent aspirated and developed pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/9\">",
"     9",
"    </a>",
"    ]. Sixty-two percent of these patients experienced recurrent pneumonias and 21 percent ultimately underwent elective total laryngectomy to prevent aspiration. No dysphagic patient achieved durable improvement across all functional measures despite rehabilitative efforts. Ultimately 66 percent of cases were gastrostomy dependent due to aspiration or poor nutrition. &nbsp;",
"   </p>",
"   <p>",
"    Newer treatment techniques, such as intensity-modulated radiation therapy (IMRT), which target the tumor with set radiation doses while limiting the dose to adjacent structures, may reduce radiation-related morbidity, particularly xerostomia. More recently, studies have shown that the avoidance of specific organs at risk is important to swallowing. Although the coverage of disease target volumes should never be sacrificed to spare noncritical avoidance structures, dose-limiting constraints to organs at risk may prove geographically possible in many cases and avoid long-term swallowing dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/7/17525?source=see_link&amp;anchor=H1493365078#H1493365078\">",
"     \"General principles of radiation therapy for head and neck cancer\", section on 'Intensity-modulated RT'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/42/30378?source=see_link&amp;anchor=H3822348#H3822348\">",
"     \"Management of late complications of head and neck cancer and its treatment\", section on 'Salivary gland damage and xerostomia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with head and neck cancer, RT-induced changes in swallowing are often characterized by early improvement followed by deterioration. Clinicians should not be misled by the early recovery of swallowing as the acute effects of edema resolve. The adverse impact of radiation may equal or exceed that associated with surgery because radiation-induced fibrosis may increase in severity for years after treatment.",
"   </p>",
"   <p>",
"    Studies comparing swallowing function in radiated patients at six months and ten years post-treatment show a similar degree of abnormality in the pharyngeal swallow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/4,11\">",
"     4,11",
"    </a>",
"    ]. These include reduced tongue base contact to the pharyngeal wall, restricted laryngeal motion, and impaired airway protection, with resultant aspiration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Other studies have shown prolonged pharyngeal bolus transit time and delayed hyoid bone elevation, which causes the upper esophageal sphincter to open early relative to the arrival of the food bolus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/11\">",
"     11",
"    </a>",
"    ]. Contributory factors to this reduced swallowing ability include tissue changes, fibrosis, and possible alterations in sensory awareness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H178953860\">",
"    <span class=\"h2\">",
"     Fibrosis and neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrosis and xerostomia are the common main sequelae of RT to the head and neck region that affect speech and swallowing. However, dysphagia after RT or chemoradiotherapy (CRT) is probably the result of both fibrosis and cranial neuropathies that cause neuromuscular dysfunction and impede swallowing physiology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/14\">",
"     14",
"    </a>",
"    ]. Early evidence supports the neuropathic contributions to posttreatment dysphagia as a result of the denervation of the suprahyoid musculature following RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/15\">",
"     15",
"    </a>",
"    ]. Moreover, data suggest that when dysphagia occurs five or more years after RT, it is usually severe and often refractory to standard swallowing therapies. Such late dysphagia is due to significant impairment to the range of motion of the hyolaryngeal complex resulting from the long-term effects of RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/42/30378?source=see_link&amp;anchor=H3822522#H3822522\">",
"     \"Management of late complications of head and neck cancer and its treatment\", section on 'Soft tissue fibrosis in the neck'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H178953867\">",
"    <span class=\"h2\">",
"     Xerostomia and mucositis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy alters the volume, consistency, and pH of secreted saliva. Saliva changes from thin secretions with a neutral pH to thick and tenacious, with increased acidity. Radiation-induced damage to the salivary glands usually causes permanent xerostomia and is one of the most disturbing adverse effects to patients because there are no good, effective long-term management strategies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/42/30378?source=see_link&amp;anchor=H3822348#H3822348\">",
"     \"Management of late complications of head and neck cancer and its treatment\", section on 'Salivary gland damage and xerostomia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute mucositis is also associated with long-term dysphagia and has been reported to be the dose-limiting toxicity of standard chemoradiotherapy regimens. Patients report thick, ropey secretions that result in gagging, regurgitation, and predispose to aspiration. High-grade mucositis resulting from intensive chemoradiotherapy protocols generally occurs early, lasts longer, is more severe, and may result in scarring and organ dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/17\">",
"     17",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H178953874\">",
"    <span class=\"h2\">",
"     Gastrostomy tube placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of prophylactic feeding tube placement continues to be controversial. Some data suggest that patients with increased weight loss should receive a feeding tube before therapy begins. Other studies suggest that excessive use of feeding tubes leads to increased long-term feeding tube dependency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/18\">",
"     18",
"    </a>",
"    ]. Current evidence suggests that even brief intervals of no oral intake decreases swallowing function and therefore should be avoided as much as possible. Thus, many clinicians prefer to defer placement of a feeding tube until a clinical need is evident [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H178953881\">",
"    <span class=\"h2\">",
"     Aspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the potentially severe effects of RT, dysphagia and aspiration are underreported and underappreciated consequences of RT and chemoradiotherapy. Although the true extent of this toxicity has not been well-documented, it has been estimated that at least 50 percent of long-term head and neck cancer survivors have dysphagia with aspiration rates up to 84 percent. Silent (insensate) aspiration has been reported in up to 80 percent of patients who aspirate with the highest rates of silent aspiration occurring more than 12 months after the completion of RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/12,20,21\">",
"     12,20,21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/24/3466?source=see_link\">",
"     \"Quality of life in head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H524543709\">",
"    <span class=\"h3\">",
"     Primary tumor site",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary site of the head and neck cancer can influence the clinical manifestations of fibrosis and xerostomia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral cavity &ndash; In patients receiving RT to the oral cavity, dry mouth may affect mastication by changes in tongue mobility, prolongation of oral transit time, and a delay in the triggering of the swallow reflex [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/3,22-25\">",
"       3,22-25",
"      </a>",
"      ]. Oropharyngeal swallowing efficiency may be affected indefinitely after RT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pharynx &ndash; Postradiation fibrosis of the pharyngeal constrictor musculature usually impairs pharyngeal motility, resulting in retention of food or residue within the pharynx, and the potential for aspiration. Patients with primary hypopharyngeal tumors have the worst swallowing outcomes after RT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tongue base and tonsil &ndash; Patients with tumors of the base of tongue or tonsil are at risk for postradiation pharyngeal dysmotility and incoordination and difficulty triggering the swallow reflex. Subsequent problems in bolus transit may result in aspiration.",
"     </li>",
"     <li>",
"      Larynx &ndash; When the larynx is in the RT field, problems with airway protection and voice changes may also necessitate intervention [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/27\">",
"       27",
"      </a>",
"      ]. Voice changes may result from reversal of the mechanical effects of the tumor, the short-term effects of edema, and the long-term effects of fibrosis. Nevertheless, patients prefer laryngeal phonation after organ preservation as compared to any of the methods used to restore oral communication after laryngectomy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/54/16231?source=see_link\">",
"       \"Alaryngeal speech rehabilitation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      RT to the larynx usually results in problems with the pharyngeal swallow, with aspiration reported in up to 80 percent of patients treated with nonsurgical organ preservation for laryngeal cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/20\">",
"       20",
"      </a>",
"      ]. Radiation-induced fibrosis can reduce the range of motion of the tongue and jaw, diminish pharyngeal wall motion, and restrict laryngeal movements, increasing the potential for aspiration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/7\">",
"       7",
"      </a>",
"      ]. In one report, almost one-half of nonlaryngectomized head and neck cancer survivors had at least some degree of aspiration, which was associated with weight loss and negative impacts on quality of life [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/12,20,21\">",
"       12,20,21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise protocols to strengthen and maintain range of motion, precision, muscle elasticity and mobility should be started prior to the initiation of RT. Patients should adhere to these established exercise protocols both during and after RT. Some patients may find the long-term use of this exercise regimen to be necessary to counter the long-term adverse effects of radiation. In at least one study, patients who performed swallowing exercises during RT had significantly higher patient-reported swallowing related quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/28\">",
"     28",
"    </a>",
"    ]. Given the evidence that supports pretreatment swallowing exercises to improve post treatment swallowing function, it is critical that patients who will be treated with radiation are referred to speech pathologists before their cancer treatment begins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An appropriate swallowing therapy program for patients with dysphagia may include the use of specific swallowing maneuvers, changes in body posture, range of motion or resistance exercises, or techniques to heighten sensory awareness and facilitate bolus transit during swallowing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/3,4,22,27,30\">",
"     3,4,22,27,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Such exercises can improve pharyngeal mobility during the swallow, resulting in enhanced pharyngeal clearance, airway protection, and decreased or absent aspiration in the majority of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/4,29,31-33\">",
"     4,29,31-33",
"    </a>",
"    ]. Despite the demonstrable improvement that is possible with this approach, many patients are not referred to speech pathologists for such a program.",
"   </p>",
"   <p>",
"    Voice therapy may be of benefit for patients with posttreatment phonation problems that cause difficulty in communication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Other complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other complications from RT that can affect speech and swallowing include trismus, dysgeusia (taste alterations), ageusia (loss of taste), dysosmia (altered sense of smell), and esophagitis. Many of these problems begin within the first two weeks of RT and worsen progressively as treatments proceed. Another complication that commonly occurs after RT is lymphedema of the head and neck. This can affect the oral",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pharyngeal anatomy and result in significant speech and swallowing dysfunction. Early experience has shown that targeted therapy that combines techniques of gentle massage, compression bandaging, skin care, and exercise has been very successful in relieving chronic edema, thus facilitating improved cosmesis and a return of speech and swallowing function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/42/30378?source=see_link\">",
"     \"Management of late complications of head and neck cancer and its treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/1/22554?source=see_link\">",
"     \"Management and prevention of complications of head and neck cancer during initial treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The magnitude of these effects varies widely, although most patients experience some impairment in both swallowing and speech production. The tissue soreness and edema associated with RT decreases sensation, interfering with the precision of oropharyngeal mobility. This in turn impairs the timing and coordination of the swallow. Articulatory imprecision and oral incoordination may slur speech and impair intelligibility. Patients frequently report a clumsiness or slowness of speech rather than dysarthria associated with articulation. Fortunately, these problems tend to subside as the mucosal irritation and edema resolve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     POSTSURGICAL COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Speech and swallowing rehabilitation is essential after resection of tumors of the head and neck. In general, surgical procedures that result in larger surgical defects produce greater deficits in speech and swallowing.",
"   </p>",
"   <p>",
"    Although the extent of the cancer resection and the resultant surgical defect will dictate the type of reconstructive procedure, reconstructive procedures that utilize flaps that are adynamic, bulky, or that overfill the surgical defect will be associated with a poorer functional outcome. Primary closure of the defect may best preserve postoperative function in selected oropharyngeal reconstructions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/36-39\">",
"     36-39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H178954006\">",
"    <span class=\"h2\">",
"     Minimally invasive techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;New endoscopic and minimally invasive surgical techniques, including transoral laser microsurgeries and transoral robotic procedures, potentially offer new opportunities to provide organ-sparing alternatives with oncologic outcomes similar to radiation-based regimens and conventional open techniques.",
"   </p>",
"   <p>",
"    These approaches may also improve long-term speech and swallowing function. Benefits have included faster recovery of swallowing function, lower incidence of aspiration pneumonia, lower rates of tracheostomy and gastrostomy, and shorter hospital stays. Patients who have failed definitive RT protocols may remain candidates for these minimally invasive surgical options in the salvage setting.",
"   </p>",
"   <p>",
"    The ability to preserve critical swallowing musculature and physiology that would otherwise be compromised by RT is likely the key benefit to maintaining the range of motion of critical swallowing organs. Early data suggest improved rehabilitative and functional outcomes after minimally invasive procedures compared with open surgical outcomes; further investigations are ongoing to corroborate findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Oral cavity and oropharyngeal cancers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical resection of cancers of the oral cavity can create complex swallowing disorders that involve both the oral and pharyngeal stages, as well as severe disturbances in speech production. Tongue mobility is the most critical component of swallowing initiation and to the subsequent triggering of the pharyngeal stage. The presence of food alone is not an adequate stimulus for triggering of the pharyngeal phase of swallowing.",
"   </p>",
"   <p>",
"    Speech and swallowing function will be affected by the degree of resection, the type of reconstruction, and the use of postoperative RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/41\">",
"     41",
"    </a>",
"    ]. In general, resections that preserve neural innervation combined with reconstructions that allow optimal residual tongue movement, especially of the back and base of tongue, will result in the best speech and swallowing functional outcome.",
"   </p>",
"   <p>",
"    Articulation and the oral stage of the swallow are most severely impaired following surgeries that suture the tongue to the floor of mouth or buccal mucosa. However, the degree of swallowing impairment often depends on the quality of the reconstruction rather than the extent of resection. The shape of oral tongue reconstruction affects postoperative speech and swallowing outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/42\">",
"     42",
"    </a>",
"    ]. As an example, slightly protuberant or convex flap shapes result in superior function after total or subtotal glossectomy compared to flat or concave flaps that provide limited structural contact necessary for articulation and bolus transit. Many patients who have undergone total glossectomy swallow better than some patients following composite resection of the tongue, floor of mouth, and mandible.",
"   </p>",
"   <p>",
"    Oral surgery that interferes with lip closure, the rotary action of the jaw, facial tone, or tongue movement will affect the oral preparatory stage of swallowing including taste, sensation, and the enjoyment associated with eating. During this stage, food is masticated and mixed with saliva. Patients can be taught to bypass this stage, although at the expense of the social and sensory enjoyment associated with eating.",
"   </p>",
"   <p>",
"    Any surgery involving the anterior floor of mouth that inhibits movement of the tip and lateral aspects of the tongue will inhibit chewing and food control, the swallowing reflex, and the pharyngeal initiation of the swallow. Similar deficits may follow resection of tumors of the posterior oral cavity (ie, tonsil or base of tongue). However, resection of these tumors more commonly interferes with the triggering of the swallow reflex, which largely occurs in the region between the anterior faucial arches and the point where the tongue base crosses the rim of the mandible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/43\">",
"     43",
"    </a>",
"    ]. Such patients will have further difficulty with oropharyngeal propulsion and pharyngeal motility, especially with the addition of postoperative radiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/41\">",
"     41",
"    </a>",
"    ]. When large areas of the pharynx must be sacrificed, the patient may not be able to move food through the pharynx at all.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;While swallowing therapy can improve oral control of the bolus and facilitate the initiation of the swallow reflex, pharyngeal dysmotility is usually permanent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/44\">",
"     44",
"    </a>",
"    ]. However, the use of specific swallowing maneuvers and postures are often successful in improving pharyngeal transit. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Complications after radiation therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Speech intelligibility can be significantly altered by total, subtotal, or partial glossectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/45-48\">",
"     45-48",
"    </a>",
"    ]. Speech therapy is effective in improving speech intelligibility, even after major resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/5\">",
"     5",
"    </a>",
"    ]. Generally, a palatal augmentation prosthesis will improve speech production and swallowing when 50 percent or more of the oral tongue is removed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Laryngeal and hypopharyngeal cancers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree of functional deficit following laryngectomy depends upon the extent of resection. While it is clear that patients who undergo either partial or total laryngectomy will experience some degree of both voice and swallowing disorders, post-treatment quality of life studies suggest that eating and swallowing seem to be of greater importance to patients than voice and speech production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/24/3466?source=see_link\">",
"     \"Quality of life in head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common problem following laryngeal surgery is the inability to elevate and close the larynx, which is critical for safe and efficient swallowing. During the pharyngeal stage of swallowing, the larynx and hyoid bone elevate and move anteriorly away from the path of the bolus to protect the airway and help open the upper esophageal sphincter, allowing the bolus to pass into the cervical esophagus. As the bolus passes through the sphincter, the larynx descends and the upper esophageal sphincter (the cricopharyngeus muscle) closes in a state of tonic contraction.",
"   </p>",
"   <p>",
"    To prevent food from entering the trachea during swallowing, three valves (the true vocal folds, the laryngeal inlet, and the epiglottis) close to prevent food from entering the trachea during swallowing, thereby avoiding aspiration. Any surgical procedure that compromises closure of the valves will result in disordered swallowing and aspiration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Myotomy of the cricopharyngeus muscle has been used to improve swallowing disorders resulting from cricopharyngeal dysfunction. However, studies are conflicting, with some showing no benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/51\">",
"     51",
"    </a>",
"    ] while others report a benefit in only a limited number of patients. In most cases, reduced cricopharyngeal opening is due to a reduced laryngeal excursion that myotomy will not improve.",
"   </p>",
"   <p>",
"    When patients are not appropriately assessed and selected, myotomy may result in significant and possibly permanent swallowing morbidity. In patients who have severe reflux, myotomy may pose a significant risk. To date, the relationship between myotomy and reflux has not been clearly established in patients with head and neck cancer; however, in noncancer patients, myotomy has not been shown to increase the occurrence of gastroesophageal reflux [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In most cases, patients with swallowing disorders related to impairment in cricopharyngeal functioning will benefit from swallowing therapy and exercise programs that focus on improving laryngeal movement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Impaired voice production also follows laryngeal surgery. Depending upon the extent of laryngeal surgery, postoperative voice disorders can range from breathiness or hoarseness to complete aphonia. Accompanying abnormalities in voice pitch and intensity may or may not be evident. Management of posttreatment voice disorders may include speech therapy alone or in combination with any one of a variety of surgical procedures designed to optimize voice production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/54/16231?source=see_link\">",
"     \"Alaryngeal speech rehabilitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Rehabilitation following laryngopharyngectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Partial laryngectomies can be either vertical hemilaryngectomy, supraglottic laryngectomy, or supracricoid partial laryngectomy depending upon the location of the tumor. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/45/41689?source=see_link&amp;anchor=H349830923#H349830923\">",
"     \"Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The larynx and hypopharynx\", section on 'Partial laryngectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who undergo vertical hemilaryngectomy (VHL) usually experience a brief period of swallowing difficulties while the surgically unaffected side gradually compensates for the damaged side. They typically have difficulty swallowing liquids due to reduced laryngeal closure. In most instances, the unaffected side will eventually cross the midline during phonation and approximate the surgically treated side for closure within a few weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, VHL produces moderate to severe impairment in vocal quality that is characterized by varying degrees of hoarseness and loudness. This is the result of the irregular vibration produced by the impaired approximation of the vocal fold and reconstructed hemilarynx. While improvement does occur in most patients, dysphonia does not fully resolve in the majority.",
"   </p>",
"   <p>",
"    Supraglottic tumors frequently require a supraglottic laryngectomy for adequate resection. Since supraglottic tumors, by the nature of their location, affect laryngeal structures above the glottis, they do not significantly affect the true vocal folds. Therefore, voice and speech are usually preserved following supraglottic resection. However, swallowing is severely affected postoperatively because airway protection has been significantly compromised, and aspiration is nearly universal. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/45/41689?source=see_link\">",
"     \"Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The larynx and hypopharynx\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recovery of swallowing function generally requires swallowing therapy using a formal hierarchy of exercises and techniques designed to facilitate and strengthen the contact between tongue base and arytenoids to prevent food or liquid from entering the airway. Although some patients recover faster, a four to six week period of time is usually required to rehabilitate swallowing following supraglottic laryngectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/56\">",
"     56",
"    </a>",
"    ]. If adequate tumor resection requires sacrifice of a significant amount of the tongue base, swallowing without aspiration may never be regained, and a total laryngectomy may be necessary.",
"   </p>",
"   <p>",
"    More recently, supracricoid partial laryngectomy with cricohyoidopexy (SCPL-CHP) or cricohyoidoepiglottopexy (SCPL-CHEP) has been advocated to control selected advanced",
"    <span class=\"nowrap\">",
"     supraglottic/transglottic",
"    </span>",
"    tumors classified as T3-T4 (",
"    <a class=\"graphic graphic_table graphicRef66619 \" href=\"mobipreview.htm?22/14/22766\">",
"     table 1",
"    </a>",
"    ) for which the conventional surgical alternative would have been total or near-total laryngectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. The avoidance of a permanent stoma for respiration and the continuity of laryngeal phonation following surgery are significant advantages of the procedure. For the majority of patients, these advantages greatly outweigh the temporary but generally severe dysphagia during the acute post-operative period, need for protracted swallowing therapy, and permanent alterations in vocal quality associated with the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/45/41689?source=see_link\">",
"     \"Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The larynx and hypopharynx\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The focus of postoperative treatment in this population is to achieve complete and timely neoglottic closure to prevent aspiration during swallowing as well as to reestablish a vibratory source for phonation. A model for swallowing rehabilitation after SCPL is available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Rehabilitation following total laryngectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to other laryngeal surgeries, patients who have undergone total laryngectomy do not routinely complain of significant swallowing problems or have aspiration because of the discontinuity of trachea and esophagus. Many patients report slower swallowing that is primarily the result of pharyngeal dysmotility, cricopharyngeal dysfunction, and reduced strength of tongue base movements following resection of the larynx and hyoid bone.",
"   </p>",
"   <p>",
"    Other nutrition-related problems have also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/61\">",
"     61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The development of a fold of mucous membrane or scar tissue at the tongue base can potentially impede swallowing. The tissue has a similar appearance to the epiglottis and has been referred to as a \"pseudoepiglottis\". At rest, the pseudoepiglottis remains flat against the tongue base; however, during swallowing, food can collect in a large pocket that is exposed between the pseudoepiglottis and the tongue base [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      As a result of hyoid bone resection and other postoperative structural changes, patients may experience difficulty with tongue movements, chewing, and bolus propulsion through the pharynx.",
"     </li>",
"     <li>",
"      A stricture within the pharynx or esophagus may narrow the passage for food transit, allowing food to collect proximal to the stricture.",
"     </li>",
"     <li>",
"      A diverticulum in the pharyngoesophageal wall may retain fluid and food resulting in the complaint of food \"sticking\" in the cervical esophagus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In all cases, postoperative complaints of swallowing difficulty after initiating oral feeding are best examined radiographically during videofluoroscopic recording to help rule-out structural abnormalities versus disease recurrence. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/38/17000?source=see_link\">",
"     \"Diagnosis and treatment of oropharyngeal dysphagia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Speech rehabilitation following total laryngectomy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/54/16231?source=see_link\">",
"     \"Alaryngeal speech rehabilitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Rehabilitation after more extensive resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Functional outcomes assessment in patients who have undergone more extensive surgeries that require complex reconstructive procedures are limited. Until recently, functional outcomes have not been adequately compared to demonstrate the benefit of one type of reconstruction over another.",
"   </p>",
"   <p>",
"    Two studies have evaluated the functional outcomes of patients after pharyngoesophageal reconstruction; one studied outcomes in patients who underwent reconstruction with an anterolateral thigh flap, while the other compared outcomes in patients with an anterolateral thigh flap versus jejunal flap reconstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/51/31545/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]x. Patients who were reconstructed using an anterolateral thigh flap had better overall functional speech and swallowing outcomes, minimal donor site morbidity, and better hospital courses than did those reconstructed with a jejunal flap. The quality of the voice and the type of swallowing deficit depended on the method of reconstruction and the resulting physiologic properties of the neopharyngeal conduit. Speech and swallowing therapy were beneficial in both patient groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H524542913\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with head and neck cancer face multiple, often severe psychological and functional problems associated with the diagnosis and treatment of their disease. Following treatment, rehabilitation and restoration of speech and swallowing are critical to optimize quality of life.",
"     </li>",
"     <li>",
"      Successful treatment for head and neck cancer and posttreatment rehabilitation are facilitated by a strong interdisciplinary team approach to management. Pretreatment evaluation and planning should involve the entire patient care and rehabilitation team including at a minimum the surgeon, radiation oncologist, medical oncologist, dentist or maxillofacial prosthodontist, speech pathologist, nurse, dietician, and social worker. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'The interdisciplinary team'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following radiation therapy to the head and neck region, fibrosis, neuropathies, mucositis, and xerostomia are the major sequelae that affect speech and swallowing. The magnitude of the problems depend upon the dose, schedule, and treatment field for radiation therapy, whether or not chemotherapy was also administered. Furthermore, clinical complications are heavily influenced by the primary site of the tumor. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Complications after radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Exercise protocols to strengthen and maintain range of motion, precision, muscle elasticity and mobility should be started prior to the onset of RT. Such exercises can improve oropharyngeal physiology during the swallow, resulting in enhanced oral transit, pharyngeal clearance, airway protection, and decreased or absent aspiration in the majority of cases. Late, severe dysphagia is uncommon but when it occurs it is often refractory to standard non-surgical rehabilitative efforts (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Speech and swallowing rehabilitation is essential following resection of tumors of the head and neck. In general, surgical procedures that result in larger surgical defects produce greater deficits in speech and swallowing. The specific deficits are based upon the primary site of the tumor and the surgical procedure used to eradicate the cancer. An appropriate, effective plan of rehabilitation depends upon thorough and accurate evaluation of speech and swallowing dysfunction.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/1\">",
"      Smith RV, Kotz T, Beitler JJ, Wadler S. Long-term swallowing problems after organ preservation therapy with concomitant radiation therapy and intravenous hydroxyurea: initial results. Arch Otolaryngol Head Neck Surg 2000; 126:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/2\">",
"      Pauloski BR, Rademaker AW, Logemann JA, et al. Pretreatment swallowing function in patients with head and neck cancer. Head Neck 2000; 22:474.",
"     </a>",
"    </li>",
"    <li>",
"     Logemann JA. Swallowing disorders after treatment for oral and oropharyngeal cancer. In: Evaluation and treatment of swallowing disorders, Berman D (Ed), Pro-Ed, Austin, TX 1998. p.251.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/4\">",
"      Mittal BB, Pauloski BR, Haraf DJ, et al. Swallowing dysfunction--preventative and rehabilitation strategies in patients with head-and-neck cancers treated with surgery, radiotherapy, and chemotherapy: a critical review. Int J Radiat Oncol Biol Phys 2003; 57:1219.",
"     </a>",
"    </li>",
"    <li>",
"     Langmore SE. Normal swallowing: The Endoscopic perspective. In: Endoscopic Evaluation and Treatment of Swallowing Disorders, Seils A (Ed), Thieme, New York 2001. p.37.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/6\">",
"      Pauloski BR, Logemann JA, Rademaker AW, et al. Speech and swallowing function after oral and oropharyngeal resections: one-year follow-up. Head Neck 1994; 16:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/7\">",
"      Pauloski BR, Rademaker AW, Logemann JA, Colangelo LA. Speech and swallowing in irradiated and nonirradiated postsurgical oral cancer patients. Otolaryngol Head Neck Surg 1998; 118:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/8\">",
"      Rademaker AW, Vonesh EF, Logemann JA, et al. Eating ability in head and neck cancer patients after treatment with chemoradiation: a 12-month follow-up study accounting for dropout. Head Neck 2003; 25:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/9\">",
"      Hutcheson KA, Lewin JS, Barringer DA, et al. Late dysphagia after radiotherapy-based treatment of head and neck cancer. Cancer 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/10\">",
"      Schwartz DL, Hutcheson K, Barringer D, et al. Candidate dosimetric predictors of long-term swallowing dysfunction after oropharyngeal intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2010; 78:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/11\">",
"      Kendall KA, McKenzie SW, Leonard RJ, Jones CU. Timing of swallowing events after single-modality treatment of head and neck carcinomas with radiotherapy. Ann Otol Rhinol Laryngol 2000; 109:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/12\">",
"      Eisbruch A, Lyden T, Bradford CR, et al. Objective assessment of swallowing dysfunction and aspiration after radiation concurrent with chemotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002; 53:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/13\">",
"      Lewin JS, Hutcheson KA, Barringer DA, et al. Dosimetric predictors of long-term dysphagia following oropharyngeal IMRT. Int J Radiat Oncol Biol Phys 2008; 72(1 Suppl):S34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/14\">",
"      Lin YS, Jen YM, Lin JC. Radiation-related cranial nerve palsy in patients with nasopharyngeal carcinoma. Cancer 2002; 95:404.",
"     </a>",
"    </li>",
"    <li>",
"     Martin S, Chung B, Bratlund C, et al. Eighteenth Annual Dysphagia Research Society Meeting Scientific Paper Sessions: Movement trajectories during percutaneous stimulation at rest of the hyolaryngeal muscles in head and neck cancer patients treated with radiation therapy. Dysphagia 2010; 25:354.",
"    </li>",
"    <li>",
"     Hutcheson KA, Lewin JS, Barringer DA, et al. Failed Organ Preservation: Chronic dysphagia five years or more after radiotherapy-based treatment of head and neck cancer. Oral presentation at 20th Annual Dysphagia Research Society Meeting. Toronto, Ontario, Canada: March 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/17\">",
"      Rosenthal DI, Trotti A. Strategies for managing radiation-induced mucositis in head and neck cancer. Semin Radiat Oncol 2009; 19:29.",
"     </a>",
"    </li>",
"    <li>",
"     Murphy BA, Lewin JS, Ridner S, et al. Mechanisms of weight loss in patients with head and neck cancer who were treated with chemotherapy, ASCO Education Book Spring, 2006. p.340.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/19\">",
"      Lewin JS. Dysphagia after chemoradiation: prevention and treatment. Int J Radiat Oncol Biol Phys 2007; 69:S86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/20\">",
"      Hutcheson KA, Barringer DA, Rosenthal DI, et al. Swallowing outcomes after radiotherapy for laryngeal carcinoma. Arch Otolaryngol Head Neck Surg 2008; 134:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/21\">",
"      Rosenthal DI, Lewin JS, Eisbruch A. Prevention and treatment of dysphagia and aspiration after chemoradiation for head and neck cancer. J Clin Oncol 2006; 24:2636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/22\">",
"      Logemann JA, Pauloski BR, Rademaker AW, Colangelo LA. Speech and swallowing rehabilitation for head and neck cancer patients. Oncology (Williston Park) 1997; 11:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/23\">",
"      Lazzara G, Lazarus C, Logemann JA. Impact of thermal stimulation on the triggering of the swallowing reflex. Dysphagia 1986; 1:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/24\">",
"      Lazarus CL, Logemann JA, Pauloski BR, et al. Swallowing and tongue function following treatment for oral and oropharyngeal cancer. J Speech Lang Hear Res 2000; 43:1011.",
"     </a>",
"    </li>",
"    <li>",
"     Allen K, Kuznicki MC, Mamel JJ. Nutrition support of the cancer patient. In: Swallowing Intervention in Oncology, Sullivan PA, Guilford AM (Eds), Singular Publishing Group, Inc, San Diego 1999. p.195.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/26\">",
"      Logemann JA, Rademaker AW, Pauloski BR, et al. Site of disease and treatment protocol as correlates of swallowing function in patients with head and neck cancer treated with chemoradiation. Head Neck 2006; 28:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/27\">",
"      Lazarus C, Logemann JA, Gibbons P. Effects of maneuvers on swallowing function in a dysphagic oral cancer patient. Head Neck 1993; 15:419.",
"     </a>",
"    </li>",
"    <li>",
"     Shinn E, Lewin JS, Barringer DB, et al. The effect of adherence to swallowing exercises on swallowing outcomes in head and neck cancer patients treated with radiotherapy.19th Annual Dysphagia Research Society Meeting. San Antonio, TX: Dysphagia, 2011:443.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/29\">",
"      Carroll WR, Locher JL, Canon CL, et al. Pretreatment swallowing exercises improve swallow function after chemoradiation. Laryngoscope 2008; 118:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/30\">",
"      Logemann JA, Rademaker AW, Pauloski BR, Kahrilas PJ. Effects of postural change on aspiration in head and neck surgical patients. Otolaryngol Head Neck Surg 1994; 110:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/31\">",
"      Lazarus CL. Effects of radiation therapy and voluntary maneuvers on swallow functioning in head and neck cancer patients. Clin Commun Disord 1993; 3:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/32\">",
"      Kulbersh BD, Rosenthal EL, McGrew BM, et al. Pretreatment, preoperative swallowing exercises may improve dysphagia quality of life. Laryngoscope 2006; 116:883.",
"     </a>",
"    </li>",
"    <li>",
"     Carnaby-Mann G, Crary M, Amdur R, Schmalfuss I. Preventative exercise for dysphagia following head and neck cancer (abstract). Dysphagia 2007; 22:381a. Data presented at the 15th Annual Dysphagia Research Society Meeting, March 8-10, 2007, Scientific Poster Sessions, Vancouver, British Columbia, Canada.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/34\">",
"      van Gogh CD, Verdonck-de Leeuw IM, Boon-Kamma BA, et al. The efficacy of voice therapy in patients after treatment for early glottic carcinoma. Cancer 2006; 106:95.",
"     </a>",
"    </li>",
"    <li>",
"     Lewin JS, Hutcheson KA, Smith BG, et al. Early experience with head and neck lymphedema after treatment for head and neck cancer. Multidisciplinary Head  &amp; Neck Cancer Symposium. Chandler, Arizona, 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/36\">",
"      Pauloski BR, Logemann JA, Rademaker AW, et al. Speech and swallowing function after anterior tongue and floor of mouth resection with distal flap reconstruction. J Speech Hear Res 1993; 36:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/37\">",
"      Logemann JA, Pauloski BR, Rademaker AW, et al. Speech and swallow function after tonsil/base of tongue resection with primary closure. J Speech Hear Res 1993; 36:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/38\">",
"      McConnel FM, Pauloski BR, Logemann JA, et al. Functional results of primary closure vs flaps in oropharyngeal reconstruction: a prospective study of speech and swallowing. Arch Otolaryngol Head Neck Surg 1998; 124:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/39\">",
"      McConnel FM, Logemann JA, Rademaker AW, et al. Surgical variables affecting postoperative swallowing efficiency in oral cancer patients: a pilot study. Laryngoscope 1994; 104:87.",
"     </a>",
"    </li>",
"    <li>",
"     Hutcheson KA, Jantharapattana K, Barringer DA. Functional and oncologic outcomes of primary versus salvage transoral laser microsurgery for supraglottic carcinoma. Ann Otol Rhinol Laryngol 2011 [submitted].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/41\">",
"      Pauloski BR, Logemann JA. Impact of tongue base and posterior pharyngeal wall biomechanics on pharyngeal clearance in irradiated postsurgical oral and oropharyngeal cancer patients. Head Neck 2000; 22:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/42\">",
"      Kimata Y, Sakuraba M, Hishinuma S, et al. Analysis of the relations between the shape of the reconstructed tongue and postoperative functions after subtotal or total glossectomy. Laryngoscope 2003; 113:905.",
"     </a>",
"    </li>",
"    <li>",
"     Logemann JA. Anatomy and physiology of normal deglutition. In: Evaluation and treatment of swallowing disorders, Berman D (Ed), Pro-Ed, Austin, TX 1998. p.29.",
"    </li>",
"    <li>",
"     Logemann JA. Deglutition disorders in cancer of the head and neck. In: and Neck Oncology: Clinical Management, Kagan AR, Miles J (Eds), Pergamon, New York 1989. p.155.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/45\">",
"      Sun J, Weng Y, Li J, et al. Analysis of determinants on speech function after glossectomy. J Oral Maxillofac Surg 2007; 65:1944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/46\">",
"      Bressmann T, Sader R, Whitehill TL, Samman N. Consonant intelligibility and tongue motility in patients with partial glossectomy. J Oral Maxillofac Surg 2004; 62:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/47\">",
"      Ruhl CM, Gleich LL, Gluckman JL. Survival, function, and quality of life after total glossectomy. Laryngoscope 1997; 107:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/48\">",
"      Furia CL, Kowalski LP, Latorre MR, et al. Speech intelligibility after glossectomy and speech rehabilitation. Arch Otolaryngol Head Neck Surg 2001; 127:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/49\">",
"      Marunick M, Tselios N. The efficacy of palatal augmentation prostheses for speech and swallowing in patients undergoing glossectomy: a review of the literature. J Prosthet Dent 2004; 91:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/50\">",
"      Hillman RE, Walsh MJ, Wolf GT, et al. Functional outcomes following treatment for advanced laryngeal cancer. Part I--Voice preservation in advanced laryngeal cancer. Part II--Laryngectomy rehabilitation: the state of the art in the VA System. Research Speech-Language Pathologists. Department of Veterans Affairs Laryngeal Cancer Study Group. Ann Otol Rhinol Laryngol Suppl 1998; 172:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/51\">",
"      Jacobs JR, Logemann J, Pajak TF, et al. Failure of cricopharyngeal myotomy to improve dysphagia following head and neck cancer surgery. Arch Otolaryngol Head Neck Surg 1999; 125:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/52\">",
"      Williams RB, Ali GN, Hunt DR, et al. Cricopharyngeal myotomy does not increase the risk of esophagopharyngeal acid regurgitation. Am J Gastroenterol 1999; 94:3448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/53\">",
"      Shaker R, Easterling C, Kern M, et al. Rehabilitation of swallowing by exercise in tube-fed patients with pharyngeal dysphagia secondary to abnormal UES opening. Gastroenterology 2002; 122:1314.",
"     </a>",
"    </li>",
"    <li>",
"     Blaugrund SM. Laryngeal framework surgery. In: Phonosurgery: Assessment and Surgical Management of Voice Disorders, Ford CN, Bless DM (Eds), Raven Press, New York 1991. p.183.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/55\">",
"      Rademaker AW, Logemann JA, Pauloski BR, et al. Recovery of postoperative swallowing in patients undergoing partial laryngectomy. Head Neck 1993; 15:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/56\">",
"      Logemann JA, Gibbons P, Rademaker AW, et al. Mechanisms of recovery of swallow after supraglottic laryngectomy. J Speech Hear Res 1994; 37:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/57\">",
"      Laccourreye H, Laccourreye O, Weinstein G, et al. Supracricoid laryngectomy with cricohyoidopexy: a partial laryngeal procedure for selected supraglottic and transglottic carcinomas. Laryngoscope 1990; 100:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/58\">",
"      Bron L, Brossard E, Monnier P, Pasche P. Supracricoid partial laryngectomy with cricohyoidoepiglottopexy and cricohyoidopexy for glottic and supraglottic carcinomas. Laryngoscope 2000; 110:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/59\">",
"      Dworkin JP, Meleca RJ, Zacharek MA, et al. Voice and deglutition functions after the supracricoid and total laryngectomy procedures for advanced stage laryngeal carcinoma. Otolaryngol Head Neck Surg 2003; 129:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/60\">",
"      Lewin JS, Hutcheson KA, Barringer DA, et al. Functional analysis of swallowing outcomes after supracricoid partial laryngectomy. Head Neck 2008; 30:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/61\">",
"      Gates GA, Ryan W, Cantu E, Hearne E. Current status of laryngectomee rehabilitation: II. Causes of failure. Am J Otolaryngol 1982; 3:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/62\">",
"      Davis RK, Vincent ME, Shapshay SM, Strong MS. The anatomy and complications of \"T\" versus vertical closure of the hypopharynx after laryngectomy. Laryngoscope 1982; 92:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/63\">",
"      Lewin JS, Barringer DA, May AH, et al. Functional outcomes after laryngopharyngectomy with anterolateral thigh flap reconstruction. Head Neck 2006; 28:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/51/31545/abstract/64\">",
"      Lewin JS, Barringer DA, May AH, et al. Functional outcomes after circumferential pharyngoesophageal reconstruction. Laryngoscope 2005; 115:1266.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3368 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.117.136.88-29CCF0041E-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_51_31545=[""].join("\n");
var outline_f30_51_31545=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H524542913\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      THE INTERDISCIPLINARY TEAM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H524543925\">",
"      PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      COMPLICATIONS AFTER RADIATION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H178953860\">",
"      Fibrosis and neuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H178953867\">",
"      Xerostomia and mucositis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H178953874\">",
"      Gastrostomy tube placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H178953881\">",
"      Aspiration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H524543709\">",
"      - Primary tumor site",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Other complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      POSTSURGICAL COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H178954006\">",
"      Minimally invasive techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Oral cavity and oropharyngeal cancers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Laryngeal and hypopharyngeal cancers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Rehabilitation following laryngopharyngectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Rehabilitation following total laryngectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Rehabilitation after more extensive resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H524542913\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3368\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3368|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/14/22766\" title=\"table 1\">",
"      TNM stage larynx",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/54/16231?source=related_link\">",
"      Alaryngeal speech rehabilitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/57/23446?source=related_link\">",
"      Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/38/17000?source=related_link\">",
"      Diagnosis and treatment of oropharyngeal dysphagia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/7/17525?source=related_link\">",
"      General principles of radiation therapy for head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/15/29946?source=related_link\">",
"      Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/1/22554?source=related_link\">",
"      Management and prevention of complications of head and neck cancer during initial treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/45/8919?source=related_link\">",
"      Management of acquired maxillary defects: Prosthetic rehabilitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/42/30378?source=related_link\">",
"      Management of late complications of head and neck cancer and its treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2037?source=related_link\">",
"      Pathogenesis and clinical manifestations of oropharyngeal dysphagia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/24/3466?source=related_link\">",
"      Quality of life in head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/45/41689?source=related_link\">",
"      Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The larynx and hypopharynx",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_51_31546="Craniovertebral joints and ligaments";
var content_f30_51_31546=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F72810&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F72810&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 630px\">",
"   <div class=\"ttl\">",
"    Craniovertebral joints and ligaments",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 610px; height: 720px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Ligaments of the atlanto-occipital and atlantoaxial joints. The tectorial membrane and the right side of the cruciate ligament of the atlas have been removed to show the attachment of the right alar ligament to the dens of vertebra C2 (axis).",
"    <br>",
"     (B) The hemisected craniovertebral region shows the median joints and membranous continuities of the ligamenta flava and longitudinal ligaments in the craniovertebral region.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from: Moore KL, Dalley AF. Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"     </div>",
"     <div class=\"contractual\">",
"      <br/>",
"      <a href=\"file://www.lww.com\">",
"       file://www.lww.com",
"      </a>",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_51_31546=[""].join("\n");
var outline_f30_51_31546=null;
var title_f30_51_31547="Causes of B12 deficiency";
var content_f30_51_31547=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F77437&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F77437&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of vitamin B12 deficiency",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Gastric abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pernicious anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastrectomy/Bariatric surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autoimmune metaplastic atrophic gastritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Small bowel disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malabsorption syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ileal resection or bypass",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Crohn's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blind loops",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pancreatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pancreatic insufficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Strict vegans",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vegetarian diet in pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Agents that block absorption",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neomycin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Biguanides (eg, metformin)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Proton pump inhibitors (eg, omeprazole)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N2O anesthesia inhibits methionine synthase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Inherited transcobalamin II deficiency",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_51_31547=[""].join("\n");
var outline_f30_51_31547=null;
var title_f30_51_31548="ACC AHA angiography for stable angina";
var content_f30_51_31548=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F63658&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F63658&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Coronary angiography for risk stratification in patients with chronic stable angina",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general",
"agreement that coronary angiography should be performed to risk",
"stratify patients with chronic stable angina in the following settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Disabling anginal symptoms (Canadian Cardiovascular Society [CCS] classes III and IV) despite medical therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; High-risk criteria on noninvasive testing independent of the severity of angina.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Survivors of sudden cardiac death or serious ventricular arrhythmia.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Symptoms and signs of heart failure.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Clinical features that suggest that the patient has a high likelihood of severe coronary artery disease.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The evidence or",
"opinion is in favor of performing coronary angiography to risk stratify",
"patients with chronic stable angina in the following settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Left ventricular ejection fraction less than 45 percent, CCS class I or II angina, and evidence, on noninvasive testing, of ischemia that does not meet high-risk criteria.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Noninvasive testing does not reveal adequate prognostic information.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIb - The evidence or",
"opinion is less well established for performing coronary angiography to",
"risk stratify patients with chronic stable angina in the following",
"settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Left ventricular ejection fraction greater than 45 percent, CCS class I or II angina, and evidence, on noninvasive testing, of ischemia that does not meet high-risk criteria.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; CCS class III or IV angina that improves to class I or II with medical therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; CCS class I or II angina but unacceptable side effects to adequate medical therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III - There is evidence",
"and/or general agreement that coronary angiography should not be",
"performed to risk stratify patients with chronic stable angina in the",
"following settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; CCS class I or II angina that responds to medical therapy and, on noninvasive testing, shows no evidence of ischemia.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Patient preference to avoid revascularization.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation 2003; 107:149.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_51_31548=[""].join("\n");
var outline_f30_51_31548=null;
var title_f30_51_31549="Updated Sydney system classification and grading of gastritis";
var content_f30_51_31549=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F58995&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F58995&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Updated Sydney system for the classification and grading of gastritis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type of gastritis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Etiologic factors",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gastritis synonyms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        <strong>",
"         Nonatrophic",
"        </strong>",
"       </td>",
"       <td rowspan=\"6\">",
"        <p>",
"         <em>",
"          Helicobacter pylori",
"         </em>",
"        </p>",
"        <p>",
"         ? Other factors",
"        </p>",
"       </td>",
"       <td>",
"        Superficial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diffuse antral gastritis (DAG)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic antral gastritis (CAG)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interstitial - follicular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypersecretory",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Type B*",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Atrophic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Autoimmune",
"       </td>",
"       <td rowspan=\"3\">",
"        Autoimmunity",
"       </td>",
"       <td>",
"        Type A*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diffuse corporal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pernicious anemia-associated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Multifocal atrophic",
"       </td>",
"       <td>",
"        <em>",
"         Helicobacter pylori",
"        </em>",
"       </td>",
"       <td>",
"        Type B*, type AB*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dietary",
"       </td>",
"       <td>",
"        Environmental",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ? Environmental factors",
"       </td>",
"       <td>",
"        Metaplastic",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Special forms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"4\">",
"        Chemical",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Chemical irritation",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        Reactive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Bile",
"       </td>",
"       <td class=\"sublist_other\">",
"        Reflux",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        NSAIDs",
"       </td>",
"       <td class=\"sublist_other\">",
"        NSAID",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        ? Other agents",
"       </td>",
"       <td class=\"sublist_other\">",
"        Type C*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Radiation",
"       </td>",
"       <td>",
"        Radiation injury",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"4\">",
"        Lymphocytic",
"       </td>",
"       <td>",
"        Idiopathic? Immune mechanisms",
"       </td>",
"       <td>",
"        Varioliform (endoscopic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gluten",
"       </td>",
"       <td>",
"        Celiac disease-associated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drug (ticlopidine)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ?",
"        <em>",
"         H. pylori",
"        </em>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"5\">",
"        Noninfectious granulomatous",
"       </td>",
"       <td>",
"        Crohn's disease",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sarcoidosis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wegener's granulomatosis and other vasculitides",
"       </td>",
"       <td>",
"        Granulomatosis with polyangiitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Foreign substances",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Idiopathic",
"       </td>",
"       <td>",
"        Isolated granulomatous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Eosinophilic",
"       </td>",
"       <td>",
"        Food sensitivity",
"       </td>",
"       <td>",
"        Allergic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ? Other allergies",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"4\">",
"        Other infectious gastritides",
"       </td>",
"       <td>",
"        Bacteria (other than",
"        <em>",
"         H. pylori",
"        </em>",
"        )",
"       </td>",
"       <td>",
"        Phlegmonous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Viruses",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fungi",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parasites",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NSAIDs: nonsteroidal antiinflammatory drugs.",
"     <br>",
"      * Alphabetic designations of gastritis were abandoned in the original presentation of the Sydney System. That approach is also recommended here. Use of \"Type B\" to denote either atrophic",
"      <em>",
"       or",
"      </em>",
"      non-atrophic gastritis is considered to be especially misleading.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Many participants favor substitution of",
"       <em>",
"        gastropathy",
"       </em>",
"       for",
"       <em>",
"        gastritis",
"       </em>",
"       to describe conditions that result from chemical injury.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dixon M, Genta R, Yardley J, Correa P; the Participants in the International Workshop on the Histopathology of Gastritis, Houston. Classification and grading of gastritis: The updated Sydney system. Am J Surg Pathol 1996; 20:1161. Copyright &copy; 1996 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_51_31549=[""].join("\n");
var outline_f30_51_31549=null;
var title_f30_51_31550="Specific rx pneumonia children";
var content_f30_51_31550=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57150&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57150&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Specific antibiotic therapy for pneumonia in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Pathogen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Parenteral therapy",
"       </td>",
"       <td class=\"subtitle1\">",
"        Oral therapy",
"        <br/>",
"        (step-down therapy or mild infection)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Streptococcus pneumoniae",
"        </em>",
"        with MICs for penicillin &le;2.0 mcg/mL",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Preferred:",
"         </strong>",
"         ampicillin (150-200 mg/kg/day every 6 hours) or penicillin (200,000-250,000 units/kg/day every 4-6 hours)",
"        </p>",
"        <p>",
"         <strong>",
"          Alternatives:",
"         </strong>",
"         ceftriaxone (50-100 mg/kg/day every 12-24 hours) (preferred for parenteral outpatient therapy) or cefotaxime (150 mg/kg/day every 8 hours); may also be effective: clindamycin (40 mg/kg/day every 6-8 hours) or vancomycin (40-60 mg/kg/day every 6-8 hours)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Preferred:",
"         </strong>",
"         amoxicillin (90 mg/kg/day in 2 doses or 45 mg/kg/day in 3 doses)",
"        </p>",
"        <p>",
"         <strong>",
"          Alternatives:",
"         </strong>",
"         second- or third-generation cephalosporin (cefpodoxime, cefuroxime, cefprozil); oral levofloxacin, if susceptible (16-20 mg/kg/day in 2 doses for children 6 months to 5 years old and 8-10 mg/kg/day once daily for children 5 to 16 years old; maximum daily dose, 750 mg) or oral linezolid (30 mg/kg/day in 3 doses for children &lt;12 years old and 20 mg/kg/day in 2 doses for children &ge;12 years old)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <em>",
"         S. pneumoniae",
"        </em>",
"        resistant to penicillin, with MICs &ge;4.0 mcg/mL",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Preferred:",
"         </strong>",
"         ceftriaxone (100 mg/kg/day every 12-24 hours)",
"        </p>",
"        <p>",
"         <strong>",
"          Alternatives:",
"         </strong>",
"         ampicillin (300-400 mg/kg/day every 6 hours), levofloxacin (16-20 mg/kg/day every 12 hours for children 6 months to 5 years old and 8-10 mg/kg/day once daily for children 5 to 16 years old; maximum daily dose, 750 mg), or linezolid (30 mg/kg/day every 8 hours for children &lt;12 years old and 20 mg/kg/day every 12 hours for children &ge;12 years old); may also be effective: clindamycin* (40 mg/kg/day every 6-8 hours) or vancomycin (40-60 mg/kg/day every 6-8 hours)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Preferred:",
"         </strong>",
"         oral levofloxacin (16-20 mg/kg/day in 2 doses for children 6 months to 5 years and 8-10 mg/kg/day once daily for children 5 to 16 years, maximum daily dose, 750 mg), if susceptible, or oral linezolid (30 mg/kg/day in 3 doses for children &lt;12 years and 20 mg/kg/day in 2 doses for children &ge;12 years)",
"        </p>",
"        <p>",
"         <strong>",
"          Alternative:",
"         </strong>",
"         oral clindamycin* (30-40 mg/kg/day in 3 doses)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Group A",
"        <em>",
"         Streptococcus",
"        </em>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Preferred:",
"         </strong>",
"         intravenous penicillin (100,000-250,000 units/kg/day every 4-6 hours) or ampicillin (200 mg/kg/day every 6 hours)",
"        </p>",
"        <p>",
"         <strong>",
"          Alternatives:",
"         </strong>",
"         ceftriaxone (50-100 mg/kg/day every 12-24 hours) or cefotaxime (150 mg/kg/day every 8 hours); may also be effective: clindamycin, if susceptible (40 mg/kg/day every 6-8 hours) or vancomycin",
"         <sup>",
"          &bull;",
"         </sup>",
"         (40-60 mg/kg/day every 6-8 hours)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Preferred:",
"         </strong>",
"         amoxicillin (50-75 mg/kg/day in 2 doses), or penicillin V (50-75 mg/kg/day in 3 or 4 doses)",
"        </p>",
"        <p>",
"         <strong>",
"          Alternative:",
"         </strong>",
"         oral clindamycin* (40 mg/kg/day in 3 doses)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <em>",
"         Stapyhylococcus aureus",
"        </em>",
"        , methicillin susceptible (combination therapy not well studied)",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Preferred:",
"         </strong>",
"         cefazolin (150 mg/kg/day every 8 hours) or semisynthetic penicillin, eg oxacillin (150-200 mg/kg/day every 6-8 hours)",
"        </p>",
"        <p>",
"         <strong>",
"          Alternatives:",
"         </strong>",
"         clindamycin* (40 mg/kg/day every 6-8 hours) or vancomycin (40-60 mg/kg/day every 6-8 hours)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Preferred:",
"         </strong>",
"         oral cephalexin (75-100 mg/kg/day in 3 or 4 doses)",
"        </p>",
"        <p>",
"         <strong>",
"          Alternative:",
"         </strong>",
"         oral clindamycin* (30-40 mg/kg/day in 3 or 4 doses)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <em>",
"         S. aureus",
"        </em>",
"        , methicillin resistant, susceptible to clindamycin (combination therapy not well studied)",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Preferred:",
"         </strong>",
"         vancomycin (40-60 mg/kg/day every 6-8 hours or dosing to achieve an AUC/MIC ratio of &gt;400) or clindamycin (40 mg/kg/day every 6-8 hours)",
"        </p>",
"        <p>",
"         <strong>",
"          Alternatives:",
"         </strong>",
"         linezolid (30 mg/kg/day every 8 hours for children &lt;12 years old and 20 mg/kg/day every 12 hours for children &ge;12 years old)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Preferred:",
"         </strong>",
"         oral clindamycin (30-40 mg/kg/day in 3 or 4 doses)",
"        </p>",
"        <p>",
"         <strong>",
"          Alternatives:",
"         </strong>",
"         oral linezolid (30 mg/kg/day in 3 doses for children &lt;12 years and 20 mg/kg/day in 2 doses for children &ge;12 years)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <em>",
"         S. aureus",
"        </em>",
"        , methicillin resistant, resistant to clindamycin (combination therapy not well studied)",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Preferred:",
"         </strong>",
"         vancomycin (40-60 mg/kg/day every 6-8 hours or dosing to achieve an AUC/MIC ratio of &gt;400)",
"        </p>",
"        <p>",
"         <strong>",
"          Alternatives:",
"         </strong>",
"         linezolid (30 mg/kg/day every 8 hours for children &lt;12 years old and 20 mg/kg/day every 12 hours for children &ge;12 years old)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Preferred:",
"         </strong>",
"         oral linezolid (30 mg/kg/day in 3 doses for children &lt;12 years and 20 mg/kg/day in 2 doses for children &ge;12 years old)",
"        </p>",
"        <p>",
"         <strong>",
"          Alternatives:",
"         </strong>",
"         none; entire treatment course with parenteral therapy may be required",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <em>",
"         Haemophilus influenza",
"        </em>",
"        , typeable (A-F) or nontypeable",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Preferred:",
"         </strong>",
"         intravenous ampicillin (150-200 mg/kg/day every 6 hours) if &beta;-lactamase negative, ceftriaxone (50-100 mg/kg/day every 12-24 hours) if &beta;-lactamase producing, or cefotaxime (150 mg/kg/day every 8 hours)",
"        </p>",
"        <p>",
"         <strong>",
"          Alternatives:",
"         </strong>",
"         intravenous ciprofloxacin (30 mg/kg/day every 12 hours) or intravenous levofloxacin (16-20 mg/kg/day every 12 hours for children 6 months to 5 years old and 8-10 mg/kg/day once daily for children 5 to 16 years old; maximum daily dose, 750 mg)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Preferred:",
"         </strong>",
"         amoxicillin (75-100 mg/kg/day in 3 doses) if &beta;-lactamase negative) or amoxicillin clavulanate (amoxicillin component, 45 mg/kg/day in 3 doses or 90 mg/kg/day in 2 doses) if &beta;-lactamase producing",
"        </p>",
"        <p>",
"         <strong>",
"          Alternatives:",
"         </strong>",
"         cefdinir, cefixime, cefpodoxime, or ceftibuten",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <em>",
"         Mycoplasma pneumoniae",
"        </em>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Preferred:",
"         </strong>",
"         intravenous azithromycin (10 mg/kg on days 1 and 2 of therapy; transition to oral therapy if possible)",
"        </p>",
"        <p>",
"         <strong>",
"          Alternatives:",
"         </strong>",
"         intravenous erythromycin lactobionate (20 mg/kg/day every 6 hours) or levofloxacin (16-20 mg/kg/day every 12 hours; maximum daily dose, 750 mg)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Preferred:",
"         </strong>",
"         azithromycin (10 mg/kg on day 1, followed by 5 mg/kg/day once daily on days 2-5)",
"        </p>",
"        <p>",
"         <strong>",
"          Alternatives:",
"         </strong>",
"         clarithromycin (15 mg/kg/day in 2 doses) or oral erythromycin (40 mg/kg/day in 4 doses); for children &gt;7 years old, doxycycline (2-4 mg/kg/day in 2 doses; for adolescents with skeletal maturity, levofloxacin (500 mg once daily) or moxifloxacin (400 mg once daily)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <em>",
"         Chlamydia trachomatis",
"        </em>",
"        or",
"        <em>",
"         Chlamydophila pneumoniae",
"        </em>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Preferred:",
"         </strong>",
"         intravenous azithromycin (10 mg/kg on days 1 and 2 of therapy; transition to oral therapy if possible)",
"        </p>",
"        <p>",
"         <strong>",
"          Alternatives:",
"         </strong>",
"         intravenous erythromycin lactobionate (20 mg/kg/day every 6 hours) or levofloxacin (16-20 mg/kg/day in 2 doses for children 6 months to 5 years old and 8-10 mg/kg/day once daily for children 5 to 16 years old; maximum daily dose, 750 mg)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Preferred:",
"         </strong>",
"         azithromycin (10 mg/kg on day 1, followed by 5 mg/kg/day once daily days 2-5)",
"        </p>",
"        <p>",
"         <strong>",
"          Alternatives:",
"         </strong>",
"         clarithromycin (15 mg/kg/day in 2 doses) or oral erythromycin (40 mg/kg/day in 4 doses); for children &gt;7 years old, doxycycline (2-4 mg/kg/day in 2 doses); for adolescents with skeletal maturity, levofloxacin (500 mg once daily) or moxifloxacin (400 mg once daily)",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Doses for oral therapy should not exceed adult doses.",
"    <div class=\"footnotes\">",
"     AUC: area under the time versus serum concentration curve; MIC: minimum inhibitory concentration.",
"     <br/>",
"     * Clindamycin resistance appears to be increasing in certain geographic areas among",
"     <em>",
"      S. pneumoniae",
"     </em>",
"     and",
"     <em>",
"      S. aureus",
"     </em>",
"     infections.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     For &beta;-lactam-allergic children.",
"    </div>",
"    <div class=\"reference\">",
"     From: Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011; 53:e25, with permission of the Infectious Diseases Society of America. Copyright &copy; 2011 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_51_31550=[""].join("\n");
var outline_f30_51_31550=null;
var title_f30_51_31551="Healthy gingiva child";
var content_f30_51_31551=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52338&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52338&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Healthy gingiva in a 6-year-old child",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 229px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    No plaque is visible on the teeth at the gingival margin (gum line). The gingiva is uniformly pink without redness or edema.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ann Griffen, DDS, MS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_51_31551=[""].join("\n");
var outline_f30_51_31551=null;
    